RSC Advances



REVIEW

View Article Online
View Journal | View Issue



Cite this: RSC Adv., 2023, 13, 23472

Benzophenones-natural metabolites with great Hopes in drug discovery: structures, occurrence, bioactivities, and biosynthesis

Sabrin R. M. Ibrahim, *\overline{O}** *\overline{A}** Duaa Fahad ALsiyud, *\overline{C}** Abdulrahman Y. Alfaeq, *\overline{C}** Shaimaa G. A. Mohamed *\overline{O}** and Gamal A. Mohamed *\overline{O}** f

Fungi have protruded with enormous development in the repository of drug discovery, making them some of the most attractive sources for the synthesis of bio-significant and structural novel metabolites. Benzophenones are structurally unique metabolites with phenol/carbonyl/phenol frameworks, that are separated from microbial and plant sources. They have drawn considerable interest from researchers due to their versatile building blocks and diversified bio-activities. The current work aimed to highlight the reported data on fungal benzophenones, including their structures, occurrence, and bioactivities in the period from 1963 to April 2023. Overall, 147 benzophenones derived from fungal source were listed in this work. Structure activity relationships of the benzophenones derivatives have been discussed. Also, in this review, a brief insight into their biosynthetic routes was presented. This work could shed light on the future research of benzophenones.

Received 27th April 2023 Accepted 31st July 2023

DOI: 10.1039/d3ra02788k

rsc.li/rsc-advances

1 Introduction

Fungi are some of the most fundamental and optimistic sources of bio-metabolites, apparently due to the biodiversity and chemical divergence of their metabolites that could be employed for pharmacological applications and drug discovery.¹⁻⁴ Yet, a huge number of metabolites with unique structural skeletons and prominent effectiveness have been found in fungi, making them one of the fascinating repositories for therapeutics and lead scaffolds.^{2,5-9} These metabolites play crucial functions in treating various disorders, such as hypercholesterolemia (statins), autoimmune diseases, cancer, depression, and infections (antibiotics and antifungal medications).⁵⁻⁹ Benzophenones (BPs) are a wide class of natural metabolites that have been reported from fungi or higher plants of different families (*e.g.*, Clusiaceae, Iridaceae,

Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia. E-mail: gahussein@kau.edu.sa




Fig. 1 Examples of benzophenone derivatives in the market and their uses.

Lauraceae, Rosaceae, Moraceae, Daphneceae, and Myrtle families). ¹⁰⁻¹³ They have phenol/carbonyl/phenol frameworks that are commonly involved in the skeletons of various natural metabolites. Many of the reported derivatives are either polyprenylated or dimeric benzophenone derivatives. Natural BPs without side chains are of rare occurrence. These metabolites are linked with OMe, –OH, prenyl, or geranyl groups. Interestingly, these metabolites possess an active carbonyl, thus they can easily react with other functionalities to form a variety of new skeletons. ¹⁴ Recently, new polyprenylated BPs with unusual, rearranged skeletons were reported from certain fungi and higher plants. ¹⁰ The research on these metabolites attracts remarkable attention due to their structural variety and diverse

^aPreparatory Year Program, Department of Chemistry, Batterjee Medical College, Jeddah 21442, Saudi Arabia. E-mail: sabrin.ibrahim@bmc.edu.sa; Tel: +966-581183034

^bDepartment of Pharmacognosy, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt. E-mail: sabreen.ibrahim@pharm.aun.edu.eg

^{*}Department of Medical Laboratories – Hematology, King Fahd Armed Forces Hospital, Corniche Road, Andalus, Jeddah 23311, Saudi Arabia. E-mail: duaaalsiyud@yahoo.com

⁴Pharmaceutical Care Department, Ministry of National Guard – Health Affairs, Jeddah 22384, Saudi Arabia. E-mail: Faegab@mngha.med.sa

^eFaculty of Dentistry, British University, El Sherouk City, Suez Desert Road, Cairo, 11837, Egypt. E-mail: shaimaag1973@gmail.com

 $\textbf{Table 1} \quad \textbf{Naturally occurring fungal benzophenones (fungal source, host, place, molecular weights, and formulae)}^a$

| Compound name | Fungus | Host (part) | Source, place | Ref. | |
|---|--|---|---|----------|--|
| Moniliphenone (1) | Monilinia fructicola Hypocreales (MSX 17022) | Leaf litter from a beech tree community | Cultured Hillsborough, NC, USA | 18 19 | |
| | Penicillium citrinum (PSU- RSPG95) | Soil sample | Rajjaprabha Dam, Surat Thani, Thailand | 20 | |
| | Fimetariella rabenhorstii (SR84-1C) | <i>Quercus brantii</i> (stems, Fagaceae) | Natural area in Kurdistan, Iran | 21 | |
| | Alternaria sonchi (S-102) | Sonchus arvensis (leaves, Asteraceae) | Russia | 22 | |
| Rabenzophenone (2) = 5-chloromoniliphenone | Fimetariella rabenhorstii (SR84-1C) | Quercus brantii (stems, Fagaceae) | Natural area in Kurdistan, Iran | 21 | |
| eorop.ne.none | Alternaria sonchi (S-102) | Sonchus arvensis (leaves, Asteraceae) | Russia | 22 | |
| 4-Hydroxy-2-(2-hydroxy-3- methoxy-5-methylbenzoyl)-6- methoxybenzaldehyde (3) | Daldinia concentrica | _ | Tokushima | 23 | |
| 2-(2,3-Dimethoxy-5- methylbenzoyl)-4-hydroxy-6- methoxybenzaldehyde (4) | Daldinia concentrica | _ | Tokushima | 23 | |
| Nidulalin B (5) | Emericella nidulans var. lata (IN 68) = Aspergillus nidulellus | Trigonella foenumgraecum (Fabaceae) | Indonesia | 24 | |
| Cercophorin A (6) | Cercophora areolata (JS 166 = UAMH 7495) | Porcupine dung | Near Bird Lake, Muskoka District, Ontario, Canada | 25 | |
| Pestalaphenone A (7) | Pestalotiopsis sp. | <i>Melia azedarach</i> (stem bark, Meliaceae) | Nanjing, Jiangsu, China | 26 | |
| Sulochrin (8) | Aspergillus sp. | Leaf litter | Near Perth, Western Australia | 27 | |
| | Aureobasidium sp. | Litter layer | Hirosawa, Japan | 28 | |
| | Penicillium sp. (PSU-RSPG99) | Soil sample | Rajjaprabha Dam, Surat Thani, Thailand | 29 | |
| | Aspergillus europaeus (WZXY- SX-4-1) | Xestospongia testudinaria (sponge, Petrosiidae) | Weizhou Island, Guangxi, China | 30 | |
| | Penicillium citrinum (HL- 5126) | Bruguiera sexangula var. rhynchopetala (Mangrove plant, Rhizophoraceae) | South China Sea | 31 | |
| | Penicillium sp. | Acanthus ilicifolius (Mangrove plant, Acanthaceae) | Beibu gulf, Guangxi, China | 32 | |
| | Aspergillus fumigatus (GZWM]Z-152) | Piece of 35 m-deep cave soil | Fanjing, Mountain of Guizhou, China | 33 | |
| | Aspergillus flavipes (PJ03-11) | Wetland mud | Panjin Red Beach National Nature Reserve, Liaoning, China | 34 | |
| Demethylsulochrin (9) | Aspergillus sp. | Leaf litter | Near Perth, Western Australia | 27 | |
| Monomethylsulochrin (10) | Rhizoctonia sp. (Cy064) | <i>Cynodon dactylon</i> (leaves, Poaceae) | Jiangsu, China | 35 | |
| | Guignardia sp. (IFB-E028) | <i>Hopea hainanensis</i> (leaves, Dipterocarpaceae) | Hainan Island, China | 36 | |
| | Aspergillus fumigatus | Solanum insanum (fruit, Solanaceae) | Central Province of Sri Lanka | 37 | |
| | Aspergillus fumigatus (GZWMJZ-152) | Piece of 35 m-deep cave soil | Fanjing, Mountain of Guizhou, China | 33 | |
| 3,5-Dichlorosulochrin (11) | Aspergillus flavipes (PJ03-11) | Wetland mud | Panjin Red Beach National Nature Reserve in Liaoning, China | 38 | |
| 3-de- <i>O</i> -Methylsulochrin (12) | Aspergillus flavipes (PJ03-11) | Wetland mud | Panjin Red Beach National Nature Reserve in Liaoning, China | 38 | |
| | Aspergillus europaeus (WZXY-SX-4-1) | Xestospongia testudinaria (sponge, Petrosiidae) | Weizhou Island, Guangxi, China | 30 | |
| | , | (r - 6-) | | 30 | |

Table 1 (Contd.)

RSC Advances

| Compound name | Fungus | Host (part) | Source, place | Ref. |
|--------------------------------------|---------------------------------------|------------------------------|------------------------------|------|
| 14-de-O-Methyl-5- | Aspergillus europaeus (WZXY- | Xestospongia testudinaria | Weizhou Island, Guangxi, | |
| methoxysulochrin (13) | SX-4-1) | (sponge, Petrosiidae) | China | |
| 5-Methoxysulochrin (14) | Aspergillus europaeus (WZXY- | Xestospongia testudinaria | Weizhou Island, Guangxi, | 30 |
| | SX-4-1) | (sponge, Petrosiidae) | China | |
| 14- <i>O</i> -Demethylsulochrin (15) | Aspergillus europaeus (WZXY- | Xestospongia testudinaria | Weizhou Island, Guangxi, | 30 |
| | SX-4-1) | (sponge, Petrosiidae) | China | |
| Hydroxysulochrin (16) | Aureobasidium sp. | Litter layer | Hirosawa, Japan | 28 |
| | Penicillium sp. | Acanthus ilicifolius | Beibu gulf, Guangxi, China | 32 |
| | | (Mangrove plant, | | |
| | | Acanthaceae) | | |
| Penibenzophenone A (17) | Penicillium citrinum (HL- | Bruguiera sexangula var. | South China Sea | 31 |
| | 5126) | rhynchopetala (Mangrove | | |
| | | plant, Rhizophoraceae) | | |
| Penibenzophenone B (18) | Penicillium citrinum (HL- | Bruguiera sexangula var. | The South China Sea | 31 |
| | 5126) | rhynchopetala (plant, | | |
| | | Rhizophoraceae) | | |
| Penibenzophenone C (19) | Penicillium sp. | Acanthus ilicifolius (plant, | Beibu gulf, Guangxi, China | 32 |
| | | Acanthaceae) | | |
| Penibenzophenone D (20) | Penicillium sp. | Acanthus ilicifolius (plant, | Beibu gulf, Guangxi, China | 32 |
| | | Acanthaceae) | | |
| 2-(3,5-Dichloro-2,6- | Aspergillus flavipes (PJ03-11) | Wetland mud | Panjin Red Beach National | 38 |
| dihydroxy-4-methylbenzoyl)- | | | Nature Reserve in Liaoning, | |
| 5-hydroxy-3-methoxybenzoic | | | China | |
| acid (21) | | | | |
| 2-(3-Chloro-4-methyl-γ- | Penicillium sp. (PSU-RSPG99) | Soil sample | Rajjaprabha Dam, Surat | 29 |
| resorcyloyl)-5-hydroxy-m- | | - | Thani, Thailand | |
| anisic acid methyl ester (22) | Aspergillus flavipes (DL-11) | Coastal sediment | Dalian, Liaoning, China | 39 |
| = Monochlorsulochrin | Aspergillus flavipes (PJ03-11) | Wetland mud | Panjin Red Beach National | 34 |
| | | | Nature Reserve, Liaoning, | |
| | | | China | |
| Dihydrogeodin (23) | Aspergillus sp. (F1) | Trewia nudiflora (seeds, | Yunnan, China | 40 |
| | 1 0 1 () | Euphorbiaceae) | • | |
| | Penicillium sp. (PSU-RSPG99) | Soil sample | Rajjaprabha Dam, Surat | 29 |
| | • ` ` , | • | Thani, Thailand | |
| | Penicillium citrinum (PSU- | Soil sample | Rajjaprabha Dam, Surat | 20 |
| | RSPG95) | • | Thani, Thailand | |
| | Aspergillus flavipes (DL-11) | Coastal sediment | Dalian, Liaoning, China | 39 |
| | Aspergillus flavipes (PJ03-11) | Wetland mud | Panjin Red Beach National | 34 |
| | | | Nature Reserve, Liaoning, | |
| | | | China | |
| Penicillanone (24) | Penicillium citrinum (PSU- | Soil sample | Rajjaprabha Dam, Surat | 20 |
| , | RSPG95) | 1 | Thani, Thailand | |
| Rhizoctonic acid (25) | Rhizoctonia sp. (Cy064) | Cynodon dactylon (leaves, | Jiangsu, China | 35 |
| , | 1 (3) | Poaceae) | • 0 / | |
| | Guignardia sp. (IFB-E028) | Hopea hainanensis (leaves, | Hainan Island, China | 36 |
| | F () | Dipterocarpaceae) | | |
| Astrophenone (26) | Astrocystis sp. (BCC 22166) | Mangrove palm Nypa | Hat Khanom-Mu Ko Thale | 41 |
| r () | , , , , , , , , , , , , , , , , , , , | . 8 | Tai National Park, Nakhon Si | |
| | | | Thammarat, Thailand | |
| Monodictyphenone (27) | Monodictys putredinis (187/ | Marine green alga | Tenerife, Spain | 42 |
| monouncyphonone (27) | 195 15 I) | manne green arga | renerne, spani | |
| | Penicillium sp. (MA-37) | Bruguiera gymnorrhiza (soil, | Hainan Island, China | 43 |
| | remember (mire) | Rhizophoraceae) | Tumum Islama, emma | 10 |
| | Penicillium albo-biverticillium | Unidentified ascidian | Manado, Indonesia | 44 |
| | (TPU1432) | omacimica ascialari | Manado, maonesia | -1-1 |
| Iso-Monodictyphenone (28) | Penicillium sp. (MA-37) | Bruguiera gymnorrhiza (soil, | Hainan Island, China | 43 |
| 130 Monotice, prictione (20) | Tementum sp. (MA-37) | Rhizophoraceae) | Haman Bana, Cillia | -10 |
| Acremonidin E (29) | Acramonium en (II-Cyan | - Kinzophoraccae) | | 45 |
| ACICIIIOIIIIIII E (23) | Acremonium sp. (LL-Cyan 416) | | | 45 |
| A (20) | Aspergillus nidulans (FGSC | _ | Marburg, Germany | 46 |
| | roperginus muununs (FUSC | | maining, defilially | 40 |
| Arugosin F (30) | Δ4) | | | |
| Arugosin F (30) Maclurin (31) | A4) Aspergillus nidulans (FGSC | _ | Marburg, Germany | 46 |

Table 1 (Contd.)

| Compound name | Fungus | Host (part) | Source, place | Re |
|--|------------------------------------|---|--|-----|
| 1,5,8- | Aspergillus nidulans (FGSC | _ | Marburg, Germany | 46 |
| Trihydroxybenzophenone | A4) | | | |
| (32) | | | | |
| 5-Hydroxy-1,10-dimethoxy-6- | Aspergillus nidulans (FGSC | _ | Marburg, Germany | 46 |
| carboxybenzophenone (33) | A4) | | _ | |
| 5-Hydroxy-1,10-dimethoxy-6- | Aspergillus nidulans (FGSC | _ | Marburg, Germany | 46 |
| carboxylmethy- | A4) | | | |
| benzophenone (34) | | Dannia Instiffere (Insert | Tabalaa Haisansita Janan | 47 |
| 2-(2,6-Dihydroxy-4- methylbenzoyl)-6- | Graphiopsis chlorocephala | Paeonia lactiflora (leaves, Paeoniaceae) | Tohoku University, Japan | 47 |
| nydroxybenzoic acid (35) | | Paeomaceaej | | |
| Cephalanone F (36) | Graphiopsis chlorocephala | Paeonia lactiflora (leaves, | Tohoku University, Japan | 47 |
| sephalanone i (30) | опирторы стогосерний | Paeoniaceae) | Tolloku Chiversity, Japan | -1/ |
| 2,2′,3,5-Tetrahydroxy-3′- | Talaromyces islandicus (EN- | Laurencia okamurai (red alga, | Coast of Qingdao, China | 48 |
| methylbenzophenone (37) | 501) | Rhodomelaceae) | | |
| 2,2',5'-Trihydroxy-3-methoxy- | Talaromyces islandicus (EN- | Laurencia okamurai (red alga, | Coast of Qingdao, China | 48 |
| y'-methylbenzophenone (38) | 501) | Rhodomelaceae) | , | |
| Peniphenone (39) | Penicillium sp. (ZJ-SY2) | Sonneratia apetala (leaves, | Zhanjiang Mangrove Nature | 49 |
| | / | Lythraceae) | Reserve, Guangdong, China | |
| Methyl peniphenone (40) | Penicillium sp. (ZJ-SY2) | Sonneratia apetala (leaves, | Zhanjiang Mangrove Nature | 49 |
| | | Lythraceae) | Reserve, Guangdong, China | |
| Methyl 2-(2,6-dihydroxy-4- | Ascomycota sp. (SK2YWS-L) | Kandelia cande (leaf, | Shankou Mangrove Nature | 50 |
| nethylbenzoyl)-3-hydroxy-5- | | Rhizophoraceae) | Reserve, Guangxi, China | |
| methoxybenzoate (41) | | | | |
| Preacredinone A (42) | Acremonium sp. (F9A015) | Suberites japonicus (sponge, | Ga-geo Island near the | 51 |
| 1 (12) | (1=61) | Suberitidae) | southwest sea of Korea | |
| Cytosporaphenone A (43) | Cytospora rhizophorae (A761) | Morinda officinalis (twigs, | Gaoyao, Guangdong, China | 52 |
| Owbianhanana A (44) | Orbigaralla natabii (BCC | Rubiaceae) | Chan Con National Barls | F-0 |
| Orbiophenone A (44) | Orbiocrella petchii (BCC 51377) | A scale-insect (Hemiptera) underside of a leaf (Poaceae) | Chae Son National Park, Lampang, Thailand | 53 |
| Cytorhizophin C (45) | Cytospora rhizophorae (A761) | Morinda officinalis (twigs, | Gaoyao, Guangdong, China | 54 |
| Sytornizopinii C (43) | Cytospora mizophorae (A701) | Rubiaceae) | Gaoyao, Guanguong, Cilina | 34 |
| | Fimetariella rabenhorstii | Quercus brantii (stems, | Natural area in Kurdistan | 21 |
| | (SR84-1C) | Fagaceae) | (Iran) | |
| Rhizophol A (46) | Cytospora rhizophorae (A761) | Morinda officinalis (twigs, | Gaoyao, Guangdong, China | 55 |
| 1 () | <i>y</i> 1 1 () | Rubiaceae) | <i>y</i> , <i>B B</i> , | |
| Eurobenzophenone A (47) | Aspergillus europaeus (WZXY- | Xestospongia testudinaria | Weizhou Island, Guangxi, | 30 |
| | SX-4-1) | (sponge, Petrosiidae) | China | |
| Eurobenzophenone B (48) | Aspergillus europaeus (WZXY- | Xestospongia testudinaria | Weizhou Island, Guangxi, | 30 |
| | SX-4-1) | (sponge, Petrosiidae) | China | |
| Eurobenzophenone C (49) | Aspergillus europaeus (WZXY- | Xestospongia testudinaria | Weizhou Island, Guangxi, | 30 |
| | SX-4-1) | (sponge, Petrosiidae) | China | |
| Wentiphenone A (50) | Aspergillus wentii (WN-11-8- | Sediment of a hypersaline | Wadi El Natrun, Egypt | 56 |
| | 1, WN-11-8-2, WN-11-5-2) | lake | | |
| Pestalotinone A (51) | Pestalotiopsis trachicarpicola | Blechnum orientale (stem, | Shatoujiao forestry center, | 57 |
| | (SCJ551) | Blechnaceae) | Shenzhen, Guangdong, China | |
| 2,6'-Dihydroxy- | Aspergillus fumigatus | Sea sediment | Shenzhen, Guangdong, | 58 |
| 2,4'dimethoxy-8'-methyl-6- | (SWZ01) | Sea seamient | China | 36 |
| nethoxy-acyl-ethyl- | (544201) | | Cimia | |
| liphenylmethanone (52) | | | | |
| Shiraone A (53) | Shiraia sp. (BYJB-1) | Selaginella delicatula (leaves, | Huangsang nature reserve, | 59 |
| , | 1 (3) | Selaginellaceae) | Shaoyang city, Hunan, China | |
| Griseophenone B (54) | Penicillium sp. (ct-28) | Corydlis tomentella (leaves, | Jinfo Mountain, Chongqing, | 60 |
| • | - | Papaveraceae) | China | |
| Griseophenone C (55) | Penicillium sp. (ct-28) | Corydlis tomentella (leaves, | Jinfo Mountain, Chongqing, | 60 |
| - , , | / | Papaveraceae) | China | |
| | Pleosporales sp. (YY-4) | <i>Uncaria rhynchophylla</i> (plant, | Jian, Jiangxi, China | 63 |
| | / | Rubiaceae) | . 5 . | |
| Griseophenone I (56) | Penicillium sp. (ct-28) | Corydlis tomentella (leaves, | Jinfo Mountain, Chongqing, | 60 |
| | | Papaveraceae) | China | |
| Sulfurasperine A (57) | Aspergillus fumigatus | Piece of 35 m-deep cave soil | Fanjing, Mountain of | 33 |
| sanarasperine ir (o) | (GZWMJZ-152) | 1 | Guizhou, China | |

Table 1 (Contd.)

RSC Advances

| Compound name | Fungus | Host (part) | Source, place | Ref. |
|--|--|--|--|------|
| (\pm)-Sulfurasperine B (58) | Aspergillus fumigatus (GZWMJZ-152) | Piece of 35 m-deep cave soil | Fanjing, Mountain of Guizhou, China | 33 |
| (\pm)-Sulfurasperine C (59) | Aspergillus fumigatus (GZWMJZ-152) | Piece of 35 m-deep cave soil | Fanjing, Mountain of Guizhou, China | 33 |
| Sulfurasperine D (60) | Aspergillus fumigatus (GZWMJZ-152) | Piece of 35 m-deep cave soil | Fanjing, Mountain of Guizhou, China | 33 |
| Pleosporone F (61) | Pleosporales sp. (YY-4) | <i>Uncaria rhynchophylla</i> (plant, Rubiaceae) | Jian, Jiangxi, China | 63 |
| 2,4,6-Trihydroxy-2',4'-dimethoxy-6'- | Pleosporales sp. (YY-4) | <i>Uncaria rhynchophylla</i> (plant, Rubiaceae) | Jian, Jiangxi, China | 63 |
| methylbenzophenone (62) Pleosporone D (63) | Pleosporales sp. (YY-4) | <i>Uncaria rhynchophylla</i> (plant, Rubiaceae) | Jian, Jiangxi, China | 63 |
| Pleosporone E (64) | Pleosporales sp. (YY-4) | Uncaria rhynchophylla (plant, Rubiaceae) | Jian, Jiangxi, China | 63 |
| Cephalanone A (65) | Graphiopsis chlorocephala | Paeonia lactiflora (leaves, Paeoniaceae) | Tohoku University, Japan | 47 |
| Cephalanone B (66) | Graphiopsis chlorocephala | Paeonia lactiflora (leaves, Paeoniaceae) | Tohoku University, Japan | 47 |
| Cephalanone C (67) | Graphiopsis chlorocephala | Paeonia lactiflora (leaves, Paeoniaceae) | Tohoku University, Japan | 47 |
| SB87-H (8- <i>O</i> -demethyl-11- dechloropestalone (68) | Pestalotiopsis trachicarpicola (SCJ551) | Blechnum orientale (stem, Blechnaceae) | Shatoujiao forestry center, Shenzhen, Guangdong, China | 57 |
| Tenellone A (69) | Diaporthe sp. | Aeonium cuneatum (stems, Crassulaceae) | El Pijaral, Tenerife, Canary Islands, Spain | 64 |
| | Phomopsis lithocarpus (FS508) | Marine sediment | Indian Ocean | 65 |
| Tenellone B (70) | Diaporthe sp. | Aeonium cuneatum (stems, Crassulaceae) | El Pijaral, Tenerife, Canary Islands, Spain | 64 |
| Tenellone C (71) | Diaporthe sp. (SYSU-HQ3) | Excoecaria agallocha (Mangrove plant, Euphorbiaceae) | Zhuhai, Guangdong, China | 14 |
| Гenellone D (72)* | Diaporthe sp. (SYSU-HQ3) | Excoecaria agallocha (Mangrove plant, Euphorbiaceae) | Zhuhai, Guangdong, China | 14 |
| Tenellone D (73)** | Phomopsis lithocarpus (FS508) | Marine sediment | Indian Ocean | 65 |
| Tenellone E (74) | Phomopsis lithocarpus (FS508) | Marine sediment | Indian Ocean | 65 |
| Tenellone F (75) | Phomopsis lithocarpus (FS508) | Marine sediment | Indian Ocean | 65 |
| Tenellone G (76) | Phomopsis lithocarpus (FS508) | Marine sediment | Indian Ocean | 65 |
| Tenellone H (77) | Phomopsis lithocarpus (FS508) | Marine sediment | Indian Ocean | 65 |
| Tenellone J (78) | Phomopsis lithocarpus (FS508) | Deep Sea sediment | Indian Ocean | 66 |
| Tenellone L (79) | Phomopsis lithocarpus (FS508) | Deep Sea sediment | Indian Ocean | 66 |
| Pestalone (80) | Pestalotia sp. (CNL-365) | Rosenvingea sp. (brown alga, Scytosiphonaceae) | Bahamas Islands | 67 |
| | Pestalotiopsis sp. (ZJ-2009-7-6) | Soft coral | South China Sea, China | 68 |
| | Pestalotiopsis sp. | <i>Melia azedarach</i> (stem bark, Meliaceae) | Nanjing, Jiangsu, China | 26 |
| | Pestalotiopsis neglecta (F9D003) | Marine sediment | Shore of Gageo, Korea | 69 |
| Pestalone B (81) | Pestalotiopsis neglecta (F9D003) | Marine sediment | Shore of Gageo, Korea | 69 |
| Pestalone C (82) | Pestalotiopsis neglecta (F9D003) | Marine sediment | Shore of Gageo, Korea | 69 |

Review

| Compound name | Fungus | Host (part) | Source, place | Ref. |
|--|--|---|--|------|
| Pestalone D (83) | Pestalotiopsis neglecta (F9D003) | Marine sediment | Shore of Gageo, Korea | 69 |
| Pestalone E (84) | Pestalotiopsis neglecta (F9D003) | Marine sediment | Shore of Gageo, Korea | 69 |
| Pestalone F (85) | Pestalotiopsis neglecta (F9D003) | Marine sediment | Shore of Gageo, Korea | 69 |
| Pestalone G (86) | Pestalotiopsis neglecta (F9D003) | Marine sediment | Shore of Gageo, Korea | 69 |
| Pestalone H (87) | Pestalotiopsis neglecta (F9D003) | Marine sediment | Shore of Gageo, Korea | 69 |
| FD549 (88) | Talaromyces cellulolyticus (BF-0307) | Soil sample | Meguro-ku, Tokyo, Japan | 70 |
| Penibenzone A (89) | Penicillium purpurogenum (IMM003) | Edgeworthia chrysantha (leaves, Thymelaeaceae) | Hangzhou Bay, Hangzhou, Zhejiang, China | 71 |
| Penibenzone B (90) | Penicillium purpurogenum (IMM003) | Edgeworthia chrysantha (leaves, Thymelaeaceae) | Hangzhou Bay, Hangzhou, Zhejiang, China | 71 |
| Arugosin H (91) | Emericella nidulans var. | Marine green alga | Sardinia, Italy, | 72 |
| | acristata | | Mediterranean Sea | |
| | Aspergillus nidulans (FGSC A4) | _ | Marburg, Germany | 46 |
| Arugosin I (92) | Aspergillus nidulans (FGSC A4) | _ | Marburg, Germany | 46 |
| 19- <i>O</i> -Methyl-22-methoxypre-shamixanthone (93) | Mericella variecolor (XSA-07- 2) | <i>Cinachyrella</i> sp. (sponge, Tetillidae) | Yongxin Island, South China Sea | 73 |
| Pre-Shamixanthone (94) | Mericella variecolor (XSA-07- 2) | <i>Cinachyrella</i> sp. (sponge, Tetillidae) | Yongxin Island, South China Sea | 73 |
| Chryxanthone A (95) | Penicillium chrysogenum (AD- 1540) | Grateloupia turuturu (red alga, Halymeniaceae) | Qingdao, China | 74 |
| Chryxanthone B (96) | Penicillium chrysogenum (AD- 1540) | Grateloupia turuturu (red alga, Halymeniaceae) | Qingdao, China | 74 |
| Pestalotinone B (97) | Pestalotiopsis trachicarpicola (SCJ551) | Blechnum orientale (stem, Blechnaceae) | Shatoujiao forestry center, Shenzhen, Guangdong, China | 57 |
| Pestalotinone C (98) | Pestalotiopsis trachicarpicola (SCJ551) | Blechnum orientale (stem, Blechnaceae) | Shatoujiao forestry center, Shenzhen, Guangdong, China | 57 |
| Pestalachloride B (99) | Pestalotiopsis adusta (L416) | Stem of an unidentified tree | Xinglong, Hainan, China | 75 |
| | <i>Pestalotiopsis</i> sp. (ZJ-2009-7-6) | Soft coral | South China Sea, China | 68 |
| | Pestalotiopsis heterocornis | <i>Phakellia fusca</i> (sponge, Bubaridae) | Xisha Islands, China | 76 |
| | Pestalotiopsis neglecta (F9D003) | Marine sediment | Shore of Gageo, Korea | 69 |
| Cephalanone D (100) | Graphiopsis chlorocephala | Paeonia lactiflora (leaves, Paeoniaceae) | Tohoku University, Japan | 47 |
| Cephalanone E (101) | Graphiopsis chlorocephala | Paeonia lactiflora (leaves, Paeoniaceae) | Tohoku University, Japan | 47 |
| Tenellone I (102) | Diaporthe lithocarpus (A740) | Morinda officinalis (twigs, Rubiaceae) | Gaoyao, Guangdong, China | 77 |
| Tenellone K (103) | Phomopsis lithocarpus (FS508) | Deep sea sediment | Indian Ocean | 66 |
| Tenellone M (104) | Phomopsis lithocarpus (FS508) | Deep sea sediment | Indian Ocean | 66 |
| Arugosin A (105) | Aspergillus rugulosus (I.M.I. 84338) | Wild | _ | 78 |
| | Emericella nidulans var. acristata | Marine green alga | Sardinia, Italy, Mediterranean Sea | 72 |
| | Aspergillus nidulans (FGSC | _ | Marburg, Germany | 46 |

Wild

A4)

84338)

Aspergillus rugulosus (I.M.I.

Arugosin B (106)

78

| Emericella nidulans var. acristata Aspergillus nidulans (FGSC — A4) Arugosin C (107) Aspergillus rugulosus (A.R.M. Wild 325) Arugosin G (108) Emericella nidulans var. Arugosin G (109) Verticillium balanoides Pinus palustris rugulosus (A.R.M. Marine green al acristata Balanol (109) Verticillium balanoides Pinus palustris rugulosus (A.R.M. Marine green al acristata Balanol (109) Verticillium balanoides Pinus palustris rugulosus (A.R.M. Marine green al acristata Balanol (109) Verticillium balanoides Pinus palustris rugulosus (A.R.M. Marine green al acristata | Mediterranean Sea Marburg, Germany 46 — 79 Iga Sardinia, Italy, Mediterranean Sea needle litter Near Hoffman, North Carolina, USA |
|---|--|
| A4) Arugosin C (107) Aspergillus rugulosus (A.R.M. Wild 325) Arugosin G (108) Emericella nidulans var. Marine green al acristata Balanol (109) Verticillium balanoides Pinus palustris r (Pinaceae) Cytosporin A (110) Cytospora rhizophorae (A761) Morinda officina | ga Sardinia, Italy, 72 Mediterranean Sea needle litter Near Hoffman, North 80 Carolina, USA |
| Arugosin C (107) Aspergillus rugulosus (A.R.M. Wild 325) Arugosin G (108) Emericella nidulans var. Marine green al acristata Balanol (109) Verticillium balanoides Pinus palustris r (Pinaceae) Cytosporin A (110) Cytospora rhizophorae (A761) Morinda officina | lga Sardinia, Italy, 72 Mediterranean Sea needle litter Near Hoffman, North 80 Carolina, USA |
| Arugosin G (108) Eméricella nidulans var. Balanol (109) Verticillium balanoides Pinus palustris r (Pinaceae) Cytosporin A (110) Cytospora rhizophorae (A761) Morinda officina | Mediterranean Sea needle litter Near Hoffman, North 80 Carolina, USA |
| (Pinaceae) Cytosporin A (110) | needle litter Near Hoffman, North 80 Carolina, USA |
| Cytosporin A (110) Cytospora rhizophorae (A761) Morinda officina | |
| Rubiaceae) | |
| Cytosporin B (111) | dis (twigs, Gaoyao, Guangdong, China 81 |
| Cytosporin C (112) | dis (twigs, Gaoyao, Guangdong, China 81 |
| Cytosporin D (113) Cytospora rhizophorae (A761) Morinda officina Rubiaceae) | dis (twigs, Gaoyao, Guangdong, China 81 |
| Cytorhizin A (114) | dis (twigs, Gaoyao, Guangdong, China 82 |
| Cytorhizin B (115) Cytospora rhizophorae (A761) Morinda officina Rubiaceae) | dis (twigs, Gaoyao, Guangdong, China 82 |
| Cytorhizin C (116) | dis (twigs, Gaoyao, Guangdong, China 82 |
| Cytorhizin D (117) | dis (twigs, Gaoyao, Guangdong, China 82 |
| Cytorhizophin A (118) Cytospora rhizophorae (A761) Morinda officina Rubiaceae) | dis (twigs, Gaoyao, Guangdong, China 54 |
| Cytorhizophin B (119) Cytospora rhizophorae (A761) Morinda officina Rubiaceae) | dis (twigs, Gaoyao, Guangdong, China 54 |
| Cytorhizophin J (120) | olaris (stem, Nansha Mangrove National 83 Nature Reserve in Guangdong, China |
| Delicoferone A (121) Delitschia confertaspora Procavia capensi (ATCC 74209) a rock hyrax, Pr | is (Dung of Dassie, Namibia 84 |
| Delicoferone B (122) Delitschia confertaspora Procavia capensi (ATCC 74209) a rock hyrax, Pr | is (Dung of Dassie, Namibia 84 |
| Acremonidin A (123) Acremonium sp. (LL-Cyan 416) | 45 |
| Hypocreales (MSX 17022) Leaf litter from community | a beech tree Hillsborough, NC, USA 19 |
| Acremonidin B (124) Acremonium sp. (LL-Cyan — 416) | - 45 |
| Acremonidin C (125) Acremonium sp. (LL-Cyan — 416) | - 49 |
| Hypocreales (MSX 17022) Leaf litter from community | a beech tree Hillsborough, NC, USA 19 |
| Acremonidin D (126) Acremonium sp. (LL-Cyan 416) | - 45 |
| Guignasulfide (127) Guignardia sp. (IFB-E028) Hopea hainanen Dipterocarpacea | |
| Aspergillus fumigatus Solanum insanu. Solanaceae) | m (fruit, Central Province of Sri Lanka 37 |
| Microsphaerin A (128) Microsphaeropsis sp. (F2076 Lake sediment and F2078) | Singapore 85 |
| Microsphaerin D (129) Microsphaeropsis sp. (F2076 Lake sediment and F2078) | Singapore 85 |
| Phomalevone B (130) $Phoma \text{ sp. } (MYC-1734 = Montane dry for NRRL 39060)$ | rest (Ohi'a) Koloko Hue Street, Kailua- 86 Kona, Hawaii Co., HI |

Table 1 (Contd.)

| Compound name | Fungus | Host (part) | Source, place | Ref. |
|--------------------------------|--|---|---|------|
| Orbiocrellone A (131) | <i>Orbiocrella petchii</i> (BCC 51377) | A scale-insect (Hemiptera) underside of a leaf (Poaceae) | Chae Son National Park, Lampang, Thailand | 53 |
| Orbiocrellone B (132) | Orbiocrella petchii (BCC 51377) | A scale-insect (Hemiptera) underside of a leaf (Poaceae) | Chae Son National Park, Lampang, Thailand | 53 |
| Orbiocrellone C (133) | Orbiocrella petchii (BCC 51377) | A scale-insect (Hemiptera) underside of a leaf (Poaceae) | Chae Son National Park, Lampang, Thailand | 53 |
| Orbiocrellone D (134) | Orbiocrella petchii (BCC 51377) | A scale-insect (Hemiptera) underside of a leaf (Poaceae) | Chae Son National Park, Lampang, Thailand | 53 |
| Orbiocrellone E (135) | Orbiocrella petchii (BCC 51377) | A scale-insect (Hemiptera) underside of a leaf (Poaceae) | Chae Son National Park, Lampang, Thailand | 53 |
| Digriseophene A (136) | Penicillium sp. (ct-28) | Corydlis tomentella (leaves, Papaveraceae) | Jinfo Mountain, Chongqing, China | 60 |
| Dipleosporone A (137) | Pleosporales sp. (YY-4) | <i>Uncaria rhynchophylla</i> (plant, Rubiaceae) | Jian, Jiangxi, China | 63 |
| Dipleosporone B (138) | Pleosporales sp. (YY-4) | <i>Uncaria rhynchophylla</i> (plant, Rubiaceae) | Jian, Jiangxi, China | 63 |
| Dipleosporone C (139) | Pleosporales sp. (YY-4) | <i>Uncaria rhynchophylla</i> (plant, Rubiaceae) | Jian, Jiangxi, China | 63 |
| Acredinone A (140) | Acremonium sp. (F9A015) | Suberites japonicus (sponge, Suberitidae) | Ga-geo Island near the southwest sea of Korea | 51 |
| Acredinone B (141) | Acremonium sp. (F9A015) | Suberites japonicus (sponge, Suberitidae) | Ga-geo Island near the southwest sea of Korea | 51 |
| Acredinone C (142) | Acremonium sp. (F9A015) | Suberites japonicus (sponge, Suberitidae) | Ga-geo Island near the southwest sea of Korea | 87 |
| Celludinone B (143) | Talaromyces cellulolyticus (BF-0307) | Soil sample | Meguro-ku, Tokyo, Japan | 70 |
| Ent-secalonic acid I (144) | Orbiocrella petchii (BCC 51377) | A scale-insect (Hemiptera) underside of a leaf (Poaceae) | Chae Son National Park, Lampang, Thailand | 53 |
| Griseophenexanthone A (145) | Penicillium sp. (ct-28) | Corydlis tomentella (leaves, Papaveraceae) | Jinfo Mountain, Chongqing, China | 60 |
| Asperphenin A (146) | Aspergillus sp. (F452) | Submerged decaying wood | Shore of Jeju Island, Korea | 88 |
| Asperphenin B (147) | Aspergillus sp. (F452) | Submerged decaying wood | Shore of Jeju Island, Korea | 88 |

bio-activities such as protein kinase, sterol O-acyltransferase, α glucosidase, proteasome, and tyrosine phosphatase inhibitory activity, plant growth inhibition, anti-nematode, antimicrobial, anti-mycobacterial, antialgal, anticoccidial, cytotoxic, antimalarial, phytotoxic, antioxidant, anti-inflammation, antiosteoclastogenic, antihyperlipidemic, immune-suppressive, and insecticidal. Additionally, they have a rich nucleophilic nucleus that could inspire many chemists and pharmacologists to synthesize more related derivatives and generate a novel compound library for developing new medicines to treat various health-related disorders.¹⁵ In 2018, Surana et al. reviewed the reported synthetic strategies for benzophenone and its derivatives. 15 Due to their better UV protection capacity, FDA (US Food and Drug Administration) and some countries have approved their use as ingredients in sunscreen combinations. 13 Also, BPs are widely included in personal care preparations (i.e., shampoos, toothpaste, sanitation products, body washes, makeup, and skin lotion) to keep the colour and scents of these preparations, as well as UV light absorbers in synthetic products such as paints and insecticides, which are exposed to sunlight.11,13 Interestingly, some BPs derivatives are available as commercial

drugs such as tolcapone (Tasmar, anti-Parkinson`s disease), ketoprofen (analgesic and antipyretic), fenofibrate (Tricor, anti-hypercholesteraemic), and sulisobenzone, benzophenone-1 (BP-1, 2,4-dihydroxybenzophenone), and oxybenzone (benzophenone-3, 2-hydroxy-4-methoxybenzophenone) (sunscreen agents)¹⁵ (Fig. 1). Commonly, BP-3 and BP-1 are utilized as stabilizers to prevent photodegradation in many commercial products and as UV filters in cosmetics and sunscreens to prohibit skin damage and sunburn.¹⁶

Various reviews focused on BPs reported from various plant families particularly those from family Clusiaceae, including their chemistry, structural determination, and bioactivities. ^{10,12,17} Also, in 2019, Mao *et al.* summarized the reported studies regarding the BPs's occurrence and fate in the aquatic systems. ¹³ It was noted that there no comprehensive review covering BPs reported from fungal origin. Therefore, the current work focused on the BPs reported from various fungal species, including their structures, sources, host, occurrence, biosynthesis, and bioactivities in the period from 1963 to April 2023 (Table 1). Here, we intended to introduce together all current knowledge on fungal benzophenones aiming at understanding

RSC Advances Review

and rationalizing their bioactivities, structures, and biosynthesis for their possible usage as leads for the synthesis and development of pharmaceutical agents.

Research methodology

Reviewing of literature was carried out through online search on ScienceDirect, Wiley Online Library, SCOPUS, Google Scholar, PubMed, Taylor & Francis, Springer, Bentham, Thieme, and JACS. The data was retrieved using "Benzophenones + Fungi", OR "Benzophenones + Biological activity" OR "Benzophenones + Biosynthesis" as keywords. All studies that reported the isolation, structural characterization, biosynthesis, and bioactivities of fungal BPs, as well as reviews and book chapters were included. The peer-reviewed journals' English language published papers from 1963 to 2023 were included. Included studies were assessed through reading their titles, abstracts, and full texts. The no full access (e.g., conference proceedings), irrelevant, and non-reviewed journals published work were excluded. For the non-English paper, the information was extracted from the English abstracts. The reported works on BPs from other sources were not included. In the current review, a total of 110 references were discussed.

Biological activities of benzophenones

Various benzophenones derivatives have been isolated from fungi obtained from different extracts using diverse chromatographic techniques and elucidated by different spectral analyses as well as Xray, CD, ECD, and chemical methods. These metabolites have been assessed for different bioactivities that have been summarized here.

3.1. Plant growth inhibitory and anti-nematode activities

Hashimoto et al. purified and characterized compounds 3 and 4 from the EtOAc extract of Daldinia concentrica using NMR, Xray, and chemical degradation (Fig. 2). These metabolites at 5 ppm completely prohibited rice root germination in husk.²³ Also, 8 exhibited moderate (LD90 50 ppm) anti-nematode potential




Fig. 2 Structures of benzophenones 1-10.

| R ₄ | R ₅ | | OH P | ł1 | | | H ₃ COO | | K ₅ | R ₁ | ₹3 | |
|----------------|----------------|----|------------------|------------------|--------------------|-----------|--------------------|--------------------|----------------|----------------|------------------|--------------------|
| Compd No. | R1 | R2 | R3 | R4 | R5 | Compd No. | R1 | R2 | R3 | R4 | R5 | R6 |
| 11 | CI | CI | ОН | ОН | COOCH3 | 16 | ОН | CH ₂ OH | н | ОН | OCH ₃ | ОН |
| 12 | н | Н | н | ОН | COOCH ₃ | 17 | ОН | OCH ₂ | CI | OCH, | OH | CH ₃ |
| 13 | н | Н | OCH ₃ | OCH ₃ | соон | 18 | OCH ₃ | OCH ₃ | н | ОН | ОН | CH ₃ |
| 14 | н | Н | OCH ₃ | OCH ₃ | COOCH ₃ | 19 | OCOCH ₃ | CH ₃ | н | ОН | CH ₃ | ОН |
| 15 | н | н | OCH ₃ | ОН | соон | 20 | OCOCH ₃ | CH ₃ | н | ОН | CH ₃ | OCOCH ₃ |

Fig. 3 Structures of benzophenones 11-20

versus Caenorhabditis elegans and inhibited germination of cress seeds at 100 ppm.²⁷

3.2. Antimicrobial, anti-mycobacterial, and antialgal activities

The microbe's resistance to the available antibiotics becomes the main health concern. Therefore, there is a pressing requirement for finding out new types of antimicrobials with unfamiliar mechanisms to overcome multidrug-resistant microbe infections.89

Sulochrin (8) and demethylsulochrin (9) were separated from the leaf litters-derived Aspergillus species EtOAc extract by SiO2 CC. Compound 97 had no antimicrobial capacity versus E. coli or phyto-pathogens: Rhizoctonia solani and Gaeumannomyces graminis var tritici (Conc. < 200 ppm).27 Two new compounds: penibenzophenones A and B (17 and 18), along with 8 were isolated from the EtOAc extract of Bruguiera sexangula var. rhynchopetala-harbouring Penicillium citrinum (HL-5126) fermentation broth. Their structures were elucidated by extensive NMR, MS, and X-ray analyses (Fig. 3). Compound 17 is an example of chlorinated benzophenones. Among these metabolites, 17 revealed weak antibacterial effectiveness versus S. aureus (MIC 20 μ g mL⁻¹).³¹

Additionally, the new benzophenone derivatives: penibenzophenones C (19) and D (20), together with 8 and 16 were separated by SiO₂/Sephadex LH-20/HPLC from the EtOAc extract of Penicillium sp. isolated Acanthus ilicifolius collected from the South China Sea and elucidated by NMR and MS analyses. Compounds 19 and 20 demonstrated antibacterial efficacy versus MRSA (MICs 3.12 and 6.25 μ g mL⁻¹, respectively), compared to ciprofloxacin (MIC 1.56 µg mL-1), whilst 8 and 16 had weak activity in the microplate assay method (Table 2).32 Compounds 22 and 23 isolated from Aspergillus flavipes DL11 were assessed for antibacterial potential against S. aureus (ATCC-43300, ATCC-29213, ATCC-33591, and ATCC-25923), E. faecalis ATCC-51299, E. faecalis ATCC-35667, and V. parahaemolyticus ATCC-17802 in the broth microdilution (Fig. 4). Interestingly, 22 revealed powerful inhibitory potential versus all S. aureus strains (MICs 1.56 to 12.5 $\mu g \text{ mL}^{-1}$) and moderate potential versus E. faecalis ATCC-51299 and ATCC-35667 (MICs 50 and 100 $\mu g \text{ mL}^{-1}$, respectively). On the other hand, 23 had a potent antibacterial capacity versus all tested strains (MICs 1.56 to 12.5 μg mL⁻¹) except V. parahaemolyticus ATCC-17802, compared to vancomycin HCl and ampicillin sodium.39

Ma et al. reported the separation of rhizoctonic acid (25), a new benzophenone derivative and the formerly reported

Table 2 Antibacterial activity of the reported fungal benzophenones^a

| | | Biological results | | |
|----------|---|------------------------------------|---|------|
| Compd no | Assay/bacterial strain | Compound | Positive control | Ref. |
| 10 | Agar dilution/ <i>H. pylori</i> | 10.0 μg mL ⁻¹ * | Ampicillin 2.0 μg mL ⁻¹ * | 35 |
| | 0 17 | 28.9 μ M * | Ampicillin 5.4 μM* | 36 |
| 19 | Microplate/MRSA | $3.12~\mu g~m L^{-1}*$ | Ciprofloxacin 1.56 μg mL ⁻¹ * | 32 |
| | Microplate/S. aureus | $6.25 \mu \mathrm{g \ mL}^{-1} *$ | Ciprofloxacin 0.39 µg mL ⁻¹ * | 32 |
| 20 | Microplate/MRSA | 6.25 μg mL ⁻¹ * | Ciprofloxacin 1.56 μg mL ⁻¹ * | 32 |
| | Microplate/S. aureus | 12.5 μg mL ⁻¹ * | Ciprofloxacin 0.39 μg mL ⁻¹ * | 32 |
| 22 | Broth microdilution/S. aureus (ATCC43300) | 12.5 μg mL ⁻¹ * | Vancomycin HCl 1.56 μg mL ⁻¹ * | 39 |
| | Broth microdilution/S. aureus (ATCC29213) | 3.13 μg mL ⁻¹ * | Ampicillin sodium 25.0 μ g mL ⁻¹ * Vancomycin HCl 0.78 μ g mL ⁻¹ * | 39 |
| | , | _ | Ampicillin sodium 6.25 μ g mL ⁻¹ * | |
| | Broth microdilution/S. aureus (ATCC33591) | 1.56 μg mL ⁻¹ * | Vancomycin HCl 1.56 μ g mL ⁻¹ * Ampicillin sodium 25.0 μ g mL ⁻¹ * | 39 |
| | Broth microdilution/S. aureus (ATCC25923) | 1.56 $\mu g \text{ mL}^{-1}*$ | Vancomycin HCl 3.13 μg mL ⁻¹ * Ampicillin sodium 0.78 μg mL ⁻¹ * | 39 |
| | Broth microdilution/E. faecalis (ATCC51299) | $50.0~\mu g~mL^{-1}*$ | Vancomycin HCl 25.0 μg mL ⁻¹ * | 39 |
| 23 | Broth microdilution/S. aureus (ATCC43300) | 6.25 μg mL ⁻¹ * | Ampicillin sodium 25.0 $\mu g \text{ mL}^{-1}*$ Vancomycin HCl 1.56 $\mu g \text{ mL}^{-1}*$ | 39 |
| | | | Ampicillin sodium 25.0 μ g mL ⁻¹ * | |
| | Broth microdilution/S. aureus (ATCC29213) | 3.13 μg mL ⁻¹ * | Vancomycin HCl 0.78 $\mu g \text{ mL}^{-1}*$ Ampicillin sodium 6.25 $\mu g \text{ mL}^{-1}*$ | 39 |
| | Broth microdilution/S. aureus (ATCC33591) | 1.56 μg mL ⁻¹ * | Vancomycin HCl 1.56 μg mL ⁻¹ * Ampicillin sodium 25.0 μg mL ⁻¹ * | 39 |
| | Broth microdilution/S. aureus (ATCC25923) | 1.56 μg mL ⁻¹ * | Vancomycin HCl 3.13 μ g mL ⁻¹ * Ampicillin sodium 0.78 μ g mL ⁻¹ * | 39 |
| | Broth microdilution/E. faecalis (ATCC51299) | 12.5 $\mu g~mL^{-1}*$ | Vancomycin HCl 25.0 μg mL ⁻¹ * | 39 |
| | Broth microdilution/E. faecalis (ATCC35667) | 12.5 μg mL ⁻¹ * | Ampicillin sodium 25.0 μ g mL ⁻¹ * Vancomycin HCl 3.13 μ g mL ⁻¹ * | 39 |
| 25 | Agar dilution/ <i>H. pylori</i> | 25.0 μg mL ⁻¹ * | Ampicillin sodium 6.25 μ g mL ⁻¹ * Ampicillin 2.0 μ g mL ⁻¹ * | 35 |
| | 0 17 | 60.2 μM* | Ampicillin 5.4 μM* | 36 |
| 28 | Disk diffusion/A. hydrophilia | $8.0 \ \mu g \ mL^{-1}*$ | Chloromycetin 4 μg mL ⁻¹ * | 43 |
| 37 | Microplate/E. coli | 4.0 μg mL ⁻¹ * | Chloramphenicol 1.0 μg mL ⁻¹ * | 48 |
| | Microplate/P. aeruginosa | $4.0 \ \mu g \ mL^{-1}*$ | Chloramphenicol 4.0 µg mL ⁻¹ * | 48 |
| | Microplate/S. aureus | $8.0 \mu \mathrm{g \ mL}^{-1} *$ | Chloramphenicol 2.0 µg mL ⁻¹ * | 48 |
| | Microplate/Vibrio alginolyticus | 4.0 μg mL ⁻¹ * | Chloramphenicol 0.5 µg mL ⁻¹ * | 48 |
| | Microplate/V. harveyi | 8.0 $\mu g \text{ mL}^{-1}*$ | Chloramphenicol 2.0 µg mL ⁻¹ * | 48 |
| | Microplate/V. parahaemolyticus | $4.0 \ \mu g \ mL^{-1}*$ | Chloramphenicol 2.0 μg mL ⁻¹ * | 48 |
| 68 | Alamar Blue/S. aureus | 10.0 μg mL ⁻¹ ** | Kanamycin 1.25 μg mL ⁻¹ ** | 57 |
| | Alamar Blue/MRSA | 10.0 μg mL ⁻¹ ** | Vancomycin 0.625 μg mL ⁻¹ ** | 57 |
| | Alamar Blue/VSE | 10.0 μg mL ⁻¹ ** | Vancomycin 1.25 μg mL ⁻¹ ** | 57 |
| | Alamar Blue/VRE | >10.0 µg mL ⁻¹ ** | Vancomycin >40.0 μg mL ⁻¹ ** | 57 |
| 80 | Serial dilution/MRSA (31956) | 12.5 μM* | Rifampin 0.03 μM* | 68 |
| | Serial dilution/MRSA (30740) | 6.25 μM* | Rifampin 0.0037 μM* | 68 |
| | Serial dilution/MRSA (31709) | 12.5 μM* | Rifampin 0.0074 μM* | 68 |
| | Serial dilution/MRSA (31007) | 12.5 μM* | Rifampin 0.0009 μM* | 68 |
| | Serial dilution/MRSA (31692) | 12.5 μM* | Rifampin 0.0037 μM* | 68 |
| | Serial dilution/B. megaterium | 0.078 μ M * | Ciprofloxacin 0.312 μM* | 68 |
| | Serial dilution/M. lysodeikticus | 6.25 μ M * | Ciprofloxacin 3.125 μM* | 68 |
| | Broth microdilution/E. coli | $3.2 \ \mu g \ mL^{-1}**$ | Streptomycin 0.7 μg mL ⁻¹ ** | 26 |
| | Broth microdilution/P. aeruginosa | 6.5 μg mL ⁻¹ ** | Streptomycin 1.0 μg mL ⁻¹ ** | 26 |
| | Broth microdilution/S. aureus | 5.0 $\mu g \text{ mL}^{-1}**$ | Penicillin 1.2 μg mL ⁻¹ ** | 26 |
| | Broth microdilution/C. glabrata | 2.6 $\mu g \text{ mL}^{-1}**$ | Amphotericin B 0.2 μg mL ⁻¹ ** | 26 |
| | Alamar Blue/S. aureus | 5.0 μg mL ⁻¹ ** | Kanamycin 1.25 μg mL ⁻¹ ** | 57 |
| | Alamar Blue/MRSA | 5.0 $\mu g \text{ mL}^{-1}**$ | Vancomycin 0.625 μg mL ⁻¹ ** | 57 |
| | Alamar Blue/VSE | $2.5 \ \mu g \ mL^{-1}**$ | Vancomycin 1.25 μg mL ⁻¹ ** | 57 |
| | Alamar Blue/VRE | >10.0 μg mL ⁻¹ ** | Vancomycin >40.0 µg mL ⁻¹ ** | 57 |
| 84 | Alamar Blue/S. aureus | 5.0 μg mL ⁻¹ ** | Kanamycin 1.25 μg mL ⁻¹ ** | 57 |
| | Alamar Blue/MRSA | 10.0 $\mu g \text{ mL}^{-1}**$ | Vancomycin 0.625 μg mL ⁻¹ ** | 57 |
| | Alamar Blue/VSE | 5.0 μg mL ⁻¹ ** | Vancomycin 1.25 μg mL ⁻¹ ** | 57 |
| | Alamar Blue/VRE | >10.0 μg mL ⁻¹ ** | Vancomycin >40.0 μg mL ⁻¹ ** | 57 |
| | | 10.0 μg mL ⁻¹ ** | Kanamycin 1.25 μg mL ⁻¹ ** | |

Table 2 (Contd.)

| | | Biological results | | |
|----------|----------------------------------|------------------------------------|--|------|
| Compd no | Assay/bacterial strain | Compound | Positive control | Ref. |
| | Alamar Blue/MRSA | 10.0 μg mL ⁻¹ ** | Vancomycin 0.625 μg mL ⁻¹ ** | 57 |
| | Alamar Blue/VSE | 10.0 μg mL ⁻¹ ** | Vancomycin 1.25 μg mL ⁻¹ ** | 57 |
| | Alamar Blue/VRE | >10.0 µg mL ⁻¹ ** | Vancomycin >40.0 μg mL ⁻¹ ** | 57 |
| 99 | Micro broth dilution/B. subtilis | 3.0 μg mL ⁻¹ * | Ciprofloxacin 0.25 μg mL ⁻¹ * | 76 |
| | Micro broth dilution/S. aureus | 3.0 μg mL ⁻¹ * | Ciprofloxacin 0.13 μg mL ⁻¹ * | 76 |
| | Alamar Blue/S. aureus | $2.5 \mu \mathrm{g \ mL}^{-1} **$ | Kanamycin 1.25 μg mL ⁻¹ ** | 57 |
| | Alamar Blue/MRSA | 1.25 μg mL ⁻¹ ** | Vancomycin 0.625 μg mL ⁻¹ ** | 57 |
| | Alamar Blue/VSE | 5.0 μg mL ⁻¹ ** | Vancomycin 1.25 μg mL ⁻¹ ** | 57 |
| | Alamar Blue/VRE | 10.0 μg mL ⁻¹ ** | Vancomycin >40.0 μg mL ⁻¹ ** | 57 |
| 127 | Agar dilution/H. pylori | 42.9 μM* | Ampicillin 5.4 μM* | 36 |
| 129 | Agar dilution/S. aureus | 1.3 μM*** | | 85 |
| | Agar dilution/MRSA | 1.0 μM*** | _ | 85 |
| | Agar dilution/E. faecalis | 1.3 μM*** | _ | 85 |
| | Agar dilution/S. pneumoniae | 3.6 μM*** | _ | 85 |
| | Agar dilution/B. subtilis | 3.0 μM*** | _ | 85 |
| | Agar dilution/M. catarrhalis | 1.3 μM*** | _ | 85 |

analogue **10** from the culture of *Rhizoctonia* sp. Cy064 associated with *Cynodon dactylon* leaf that were elucidated using various spectral analyses. These metabolites were *in vitro* assessed of their antibacterial potential *versus Helicobacter pylori*, including 5 clinically isolated and one reference ATCC 43504 strains in the agar dilution method. These compounds showed antibacterial influence *versus* all tested strains (MICs 25.0 to 10.0 μg mL⁻¹) compared to ampicillin (MIC 2.0 μg mL⁻¹).

Investigation of *Penicillium* sp. MA-37 harboring *ruguiera* gymnorrhiza led to separation of a new benzophenone; isomonodictyphenone (28), in addition to 27 from the EtOAc extract using $SiO_2/Sephadex\ LH-20/PR-18\ CC$ and preparative TLC. Compound 28 differed from 27 mainly in the positions of ring A substituents. Compound 28 demonstrated antibacterial efficacy *versus Aeromonas hydrophilia* (MIC 8 $\mu g\ mL^{-1}$) in comparison to chloromycetin (MIC 4 $\mu g\ mL^{-1}$).




Fig. 4 Structures of benzophenones 21-30.

Two new benzophenone derivatives; 37 and 38 were isolated from the EtOAc extract of *Laurencia okamurai-associated Talar-omyces islandicus* EN-501 by SiO₂/Sephadex LH-20 CC and HPLC and assigned by NMR and X-ray analyses (Fig. 5).

Compound 37 revealed potent effectiveness *versus* human pathogens; *E. coli*, *P. aeruginosa*, and *S. aureus* and aquatic bacteria; *Vibrio alginolyticus*, *V. harveyi*, and *V. parahaemolyticus* (MICs ranged from 4.0 to 8.0 μ g mL⁻¹) in the microplate assay, however, 38 had weak potential *versus* the tested strain (MIC > 64 μ g mL⁻¹) in comparison to chloramphenicol (MICs ranged from 0.5 to 4 μ g mL⁻¹), indicating that the C-3 methoxylation weakened the activity (37 *vs.* 38).⁴⁸ *Diaporthe* sp. SYSU.HQ3 yielded tenellone C (71) that possessed inhibitory potential *versus* MptpB (*Mycobacterium tuberculosis* protein tyrosine phosphatase B) (IC₅₀ 5.2 μ M).⁹⁰

Pestalone (80), a new antibiotic derivative was biosynthesized by the brown alga *Rosenvingea* sp. associated *Pestalotia* sp. in a mixed fermentation with an antibioticresistant unidentified marine bacterium CNL-365. Besides,




Fig. 5 Structures of benzophenones 31–45.

Review RSC Advances

this compound was not produced by the individual strains, suggesting its fungal production is boosted by bacterial competition. It was isolated by RP-18/Sephadex LH-20/SiO2 CC and assigned using spectral, chemical, and Xray analyses. It featured a di-chlorinated benzene moiety. Interestingly, 80 possessed potent antibacterial potential versus vancomycinresistant Enterococcus faecium (VREF) and MRSA (methicillinresistant S. aureus) (MICs 78 and 37 ng mL⁻¹, respectively) that should be further assessed in more advanced models of infectious disease.67 Furthermore, chromatographic separation of Pestalotiopsis sp. ZJ.2009.7.6's EtOAc extract using SiO₂ and Sephadex LH-20 CC yielded 80 and 99 that were established by NMR tools. Compound 80 exhibited selective and moderate capacities versus various MRSA-31007, 30740, 31709, 31692, 31956) (MICs 6.25-12.5 µM) compared to rifampin (0.0009-0.03 μM), however, its structure-related analogue 99 had weak efficacy versus S. aureus in a serial dilution technique using 96-well microtiter plates. On the other side, only 80 possessed selective potential versus Micrococcus lysodeikticus and B. megaterium (MICs 6.25 and 0.078 µM, respectively), comparing to ciprofloxacin (MICs 3.125 and 0.312 μ M, respectively), indicating that the methoxy or aldehyde group influenced the activity.68 In another study by Li et al., 99 reported from Pestalotiopsis adusta was found to have significant effectiveness versus plant pathogens; Verticillium aibo-atrum, Fusarium culmorum, and Gibberella zeae (MICs 7.9, 4.7, and 1.1 µM, respectively).75 Besides, it displayed antibacterial efficacy versus S. aureus and B. subtilis (MICs 3.0 μg mL⁻¹) relative to ciprofloxacin (MICs 0.13 and $0.25 \,\mu g \, mL^{-1}$, respectively). To In 2017, Song et al. purified 7 as a new benzophenone, alongside with 80 from solid cultures EtOAc extract of Pestalotiopsis sp. inhabited Melia azedarach utilizing SiO₂/Sephadex LH-20 CC and preparative RP-HPLC. They were investigated for antimicrobial capacity versus B. subtilis ATCC6633, S. aureus ATCC25923, E. coli ATCC25922, P. aeruginosa ATCC9027, C. glabrata ATCC90030 in the broth microdilution method. Compound 80 also demonstrated remarkable activity versus C. glabrata (MIC₅₀ 2.6 μ g mL⁻¹).²⁶ In 2022, Jiang et al. separated new pestalone-related benzophenones; 51, 97, and 98, along with 68, 80, 84, 85, and 99 from Pestalotiopsis trachicarpicola SCJ551 culture EtOAc extract using SiO₂/RP-18/Sephadex LH-20 CC and HPLC that were established by spectroscopic analyses.⁵⁷ Compounds 51 and 97-99 had activity versus S. aureus ATCC-6548, MRSA, Enterococcusfaecium, and vancomycin-resistance E. faecium (MICs 1.25–10.0 $\mu g \text{ mL}^{-1}$). It was revealed that the C-14 aldehyde reduction into oxymethyl increased the activity. Also, the chlorination slightly increased the antibacterial potential (85 vs. 80 and 84 vs. 68).57 The new metabolites: acremonidins A-E (29 and 122-125) purified from the MeOH extract of Acremonium sp. LL-Cyan 416 by RP-18 CC and HPLC possessed moderate antibiotic activity versus MRS and VRE (vancomycinresistant *Enterococci*) (MICs ranging from 8.0 to 64.0 µg mL⁻¹) in the broth dilution method, whereas 122 was the most active (MICs $8.0-32.0 \,\mu g \, mL^{-1}$). The C-6 acetyl group was important for retaining potency (122 vs. 123).45

Scheme 1 Biosynthetic pathway of compounds 91, 105, 106, and 108 from chrysophanol.⁷²

Emericella nidulans var. acristata obtained from a Mediterranean green alga yielded **91**, **105**, **106**, and **108** that were purified from the culture EtOAc extract using SiO₂/Sephadex LH-20 CC/HPLC. These metabolites were assessed for antifungal, antibacterial, and antialgal potential (Conc. 50 µg per disk) in the agar diffusion method. Compound **91** exhibited antifungal and antialgal potential *versus Mycotypha microspora* and *Chlorella fusca*, respectively (IZD 3.0 and 2.0 mm, respectively), whereas **105** and **106** (as a mixture) displayed antibacterial efficacy *versus Bacillus megaterium* (4.0 mm). Arugosin H (**91**) was proposed to be originated from an anthrone; chrysophanol that undergoes oxidative cleavage to give an aldehyde group, with subsequent hydroxylation and C-prenylation (Scheme 1). Further, the aldehyde group is converted to a hemiacetal function to produce the other tricyclic and prenylated metabolites **105**, **106**, and **108**.

From Cytospora rhizophorae A761 associated with Morinda officinalis, cytosporins A-D (110-113), novel benzophenone derivatives were separated. Compounds 110-113 are hemiterpenoid-benzophenone conjugated hetero-dimers, having an unrivalled eight/seven-membered ring system. Their structures were characterized based on spectroscopic, ECD, and Xray analyses. Their configuration was assigned as $2^{\prime}R$ for **110** and **111**, 7R/2'R for **112**, and 7S/2'R for **113**. These metabolites had no significant antibacterial potential versus E. coli and S. aureus even at Conc. 250 $\mu g \text{ mL}^{-1}.81$ From the same fungus, Liu et al. also reported the separation of cytorhizins A-D (114-117), novel polyketide heterodimers by SiO₂/RP-18/ Sephadex LH-20 CC and RP-HPLC. These compounds have uncommon 6/6/5/6/7 or 6/6/5/6/8 pentacyclic ring skeleton forming a fascinating cage-like skeleton, involving a highly substituted benzophenone scaffold and a poly-oxygenated isopentyl moieties that were assigned by spectroscopic and Xray analyses. These compounds possessed no notable effectiveness

Scheme 2 Biosynthetic pathway of 45 and 110–118 from monodictyphenone (27).^{54,81,82} A: Functionality transformation; B: aldol condensation; C: reverse prenylation; D: dihydroxylation; E: hemiketalization; F: C-1 OH ketalization; G: C-2 OH ketalization; H: chlorination; I: methylation; J: esterification; K: prenylation; L: intramolecular lactonization; M: carboxylic acid reduction; N: etherification; O: carbonyl reduction; P: reduction or functional group transformation; Q: oxidation; R: hemi-acetalization.

versus S. aureus CMCC-26003 and E. coli ATCC-8739 even at Conc. 100 $\mu M.^{82}$

Further, Liu *et al.* identified a novel pair of enantiomeric hemiterpene-benzophenones; (+)/(-)-cytorhizophin A (118), as well as cytorhizophin B (119) that featured an unprecedented 6/7/6/7 tetracyclic fused ring system, in addition to related precursor 45 from *C. rhizophorae* A76.⁵⁴ Their structures were assigned by spectroscopic, X-ray, and ECD. They had no antibacterial potential against *E. coli* and *S. aureus*.⁵⁴

It was proposed that monodictyphenone (27) affords cytorhizophin C (45) and VIII. Further, the selective oxidation and prenylation generate hybrid intermediates IX and X, which then undergo cyclization with subsequent dihydroxylation/spontaneous ketalization to give 118 and 119 (Scheme 2). Also, 114–117 originate from 27 through series of reactions to install the propionyl moiety⁵⁴ (Scheme 2). Then, aldol condensation and a sequence of reverse prenylation, dihydroxylation, and hemi-ketalization accomplish the cagelike benzophenol core, giving a precursor (V). Further, the

regioselective ketalization in C-1 or C-2 free OH group results in 114 and VI, respectively. On the other side, 115–117 are produced from III through methylation, esterification, and chlorination, respectively. In the same manner, 110–113 are generated from precursor VII, which is formed from 27 by including hemiterpene nucleus through stereoselective dihydroxylation and chemo-selective prenylation. Its intramolecular lactonization results in 111, whereas 110 is produced from VII by carboxylic acid reduction and etherification. Further, 112 and 113 are generated from 110 by carbonyl reduction.

Guignasulfide (127), a first S-having benzophenone dimer and the formerly reported 10 and 25 were separated from the culture of *Hopea hainanensis* leaves-accompanied *Guignardia* sp. utilizing SiO₂/RP-18/Sephadex LH-20 CC. Compounds 10, 25, and 127 revealed moderate growth inhibition on *Helicobacter pylori* (MICs 28.9, 60.2, and 42.9 μ M, respectively), compared to ampicillin (MIC 5.4 μ M).³⁶

Bioassay-directed separation using MRSA whole cell assay resulted in separation of two novel benzophenone dimers, microsphaerins A and D (128 and 129) from the soil-derived Microsphaeropsis sp. by HPLC. Their structures were elucidated using spectral and X-ray analyses. In the MRSA whole cell assay, 128 and 129 had antibacterial potential (IC₉₀ 3 and 1 μ M, respectively), therefore, 129 was further assessed versus Gram positive (S. aureus ATCC25923, MRSA ATCC33591, E. faecalis ATCC51299, S. pneumoniae ATCC 49619, and B. subtilis ATCC6633) and Gram negative (E. coli ATCC25922, K pneumoniae ATCC10031, M. catarrhalis ATCC49143, H. influenzae ATCC49247, and P. aurogenosa ATCC27853). Compound 129 was found to have notable effectiveness various Gram positive strains (IC90 ranged from 1.0 to 3.6 µM) and inactive versus Gram negative strain except for Moraxella catarrhalis (IC₉₀ 1.3 μM).85 The EtOAc extract of the Hawaiian isolate of *Phoma* sp. MYC-1734 yielded phomalevone B (130) that was separated using Sephadex LH-20 and HPLC and characterized by NMR, MS, and ECD analyses. Compound 130 with bis-benzophenone skeleton displayed antimicrobial potential versus B. subtilis, S. aureus, C. albicans, and E. coli at 100 µg per disk (IZDs ranged from 18-38 mm) in the agar disk diffusion assay (Conc. 100 μg per disk).86

3.3. Cytotoxicity activity

Cancer is one of the most leading causes of death world-wide. In 2018, 9.6 million deaths because of cancer were stated according to WHO (World Health Organization). All over the world, it is estimated that ≈18.1 million cancer patients are present and this is expected to increase to 24 million in the coming decades. Since the 1980s, cancer mortality has steadily increased because of various factors, including environmental conditions and dietary habits. The most frequent and efficient cancer treatment strategies include chemotherapy and radiation therapy and surgical operation for early-stage cancers. Unfortunately, within a few years after cancer treatment, recurrence is observed with a rate of up to 70% according to cancer stages and types. Actually, the management of

Table 3 Cytotoxic activity of the reported fungal benzophenones

| | | Biological results (IC ₅₀ , μM) | | | | | |
|-----------------|---|--|------------------------------------|----------|--|--|--|
| Compd no | Cell line ^a | Compound | Positive control | Ref. | | | |
| 10 | $\mathrm{HepG2}^a$ | 63.5 | 5-Fu 19.2 | 36 | | | |
| 25 | $HepG2^a$ | 60.2 | 5-Fu 19.2 | 36 | | | |
| 68 | A549 ^a | 1.8 | Adriamycin 0.49 | 57 | | | |
| | HeLa ^a | 2.0 | Adriamycin 0.11 | 57 | | | |
| | HepG2 ^a | 2.2 | Adriamycin 0.79 | 57 | | | |
| | MCF-7 ^a | 2.0 | Adriamycin 0.43 | 57 | | | |
| 90 | Vero ^a A549 ^a | 1.5 | Admin myssin 0 40 | 57 57 | | | |
| 80 | HeLa ^a | 3.7 5.1 | Adriamycin 0.49 Adriamycin 0.11 | 57 57 | | | |
| | HepG2 ^a | 4.5 | Adriamycin 0.79 | 57 | | | |
| | MCF-7 ^a | 10.4 | Adriamycin 0.43 | 57 | | | |
| | Vero ^a | 1.7 | | 57 | | | |
| | PANC-1 ^a | 14.0 | 5-Fu 15.0 | 57 | | | |
| 81 | PANC-1 ^a | 26.0 | 5-Fu 15.0 | 69 | | | |
| 83 | PANC-1 ^a | 7.6 | 5-Fu 15.0 | 69 | | | |
| 84 | PANC-1 ^a | 7.2 | 5-Fu 15.0 | 69 | | | |
| | PANC-1 ^a | 4.8 | Cisplatin 4.0 | 69 | | | |
| | A549 ^a | 7.8 | Cisplatin 12.0 | 69 | | | |
| | HCT-116 ^a | 5.5 | Cisplatin 13.0 | 69 | | | |
| | MCF-7 ^a | 7.5 | Cisplatin 22.0 | 69 | | | |
| | DU-145 ^a | 14.0 | Cisplatin 1.9 | 69 | | | |
| | HepG2 ^a | 23.0 | Cisplatin 10.0 | 69 | | | |
| | A549 ^a HeLa ^a | 3.8 | Adriamycin 0.49 | 57 57 | | | |
| | HeLa HepG2 ^a | 3.3 5.4 | Adriamycin 0.11 Adriamycin 0.79 | 57 57 | | | |
| | MCF-7 ^a | 5.4 | Adriamycin 0.43 | 57 57 | | | |
| | Vero ^a | 2.1 | — | 57 | | | |
| 85 | PANC-1 ^a | 14.0 | 5-Fu 15.0 | 69 | | | |
| | PANC-1 ^a | 13.0 | Cisplatin 4.0 | 69 | | | |
| | $A549^a$ | 14.0 | Cisplatin 12.0 | 69 | | | |
| | HCT-116 ^a | 10.0 | Cisplatin 13.0 | 69 | | | |
| | MCF-7 ^a | 11.0 | Cisplatin 22.0 | 69 | | | |
| | DU-145 ^a | 21.0 | Cisplatin 1.9 | 69 | | | |
| | HepG2 ^a | 37.0 | Cisplatin 10.0 | 69 | | | |
| | A549 ^a | 5.7 | Adriamycin 0.49 | 57 | | | |
| | HeLa ^a | 4.7 | Adriamycin 0.11 | 57 | | | |
| | HepG2 ^a | 5.5 | Adriamycin 0.79 | 57 | | | |
| | MCF-7 ^a Vero ^a | 9.7 3.2 | Adriamycin 0.43 | 57 57 | | | |
| 86/87 mixture | PANC-1 ^a | 14.0 | — 5-Fu 15.0 | 69 | | | |
| 60/67 IIIIXture | PANC-1 ^a | 22.0 | Cisplatin 4.0 | 69 | | | |
| | A549 ^a | 18.0 | Cisplatin 12.0 | 69 | | | |
| | HCT-116 ^a | 19.0 | Cisplatin 13.0 | 69 | | | |
| | MCF-7 ^a | 22.0 | Cisplatin 22.0 | 69 | | | |
| | DU-145 ^a | 28.0 | Cisplatin 1.9 | 69 | | | |
| 99 | BGC-823 ^a | 6.8 | Adriamycin 1.5 | 76 | | | |
| | $H460^a$ | 23.6 | Adriamycin 1.0 | 76 | | | |
| | PC-3 ^a | 28.1 | Adriamycin 1.8 | 76 | | | |
| | SMMC-7721 ^a | 7.9 | Adriamycin 2.2 | 76 | | | |
| 127 | HepG2 ^a | 5.2 | 5-Fu 19.2 | 36 | | | |
| 129 | CHO ^a | 9 | _ | 85 | | | |
| | $\mathrm{HepG2}^a$ $\mathrm{MRC5}^a$ | 25 | _ | 85 | | | |
| | MRC5 HEK293 ^a | 13 20 | _ | 85 85 | | | |
| 146 | RKO ^a | 0.8 | Etoposide 3.3 | 85 88 | | | |
| 140 | SNU638 ^a | 4.8 | Etoposide 3.3 Etoposide 0.3 | 88 | | | |
| | SK-HEP-1 ^a | 2.9 | Etoposide 0.3 Etoposide 0.4 | 88 | | | |
| | MAD-MB-231 ^a | 7.0 | Etoposide 0.4 Etoposide 10.1 | 88 | | | |
| 147 | RKO ^a | 1.1 | Etoposide 3.3 | 88 | | | |
| | SNU638 ^a | 8.0 | Etoposide 0.3 | 88 | | | |
| | SK-HEP-1 ^a | 3.5 | Etoposide 0.4 | 88 | | | |
| | | | _ | | | | |

Table 3 (Contd.)

| | | Biological re | | |
|----------|-------------------------|---------------|------------------|------|
| Compd no | Cell line ^a | Compound | Positive control | Ref. |
| | MAD-MB-231 ^a | 9.7 | Etoposide 10.1 | 88 |
| | PKO^b | 0.93 | Etoposide 1.96 | 95 |
| | $HCT-116^b$ | 3.12 | Etoposide 0.66 | 95 |
| | $\mathrm{SW480}^b$ | 2.37 | Etoposide 1.11 | 95 |
| | ${ m Ls174T}^b$ | 6.36 | Etoposide 0.48 | 95 |
| | $CCD-841CoN^b$ | 47.18 | Etoposide 8.71 | 95 |
| | CCD-18Co ^b | 39.11 | Etoposide 18.42 | 95 |

^a MTT assay. ^b SRB assay; 5-Fu: 5-fluorouracil.

recurrent cancer could be hard because of their increased aggression and metastatic capacity caused by their impedance to formerly utilized drugs.⁹⁵

BPs were tested for their cytotoxic capacity against various cancer cell lines using MTT or SRB assay. These reports were highlighted below (Table 3).

Ming *et al.* purified a new benzophenone, digriseophene A (2) and formerly reported **54–56** from *Corydlis tomentella*-derived *Penicillium* sp. ct28 that were established by HRESIMS and NMR analyses. The potential cytotoxic activity of these compounds was evaluated *versus* A549, Eca109, HepG2, and MDA-MB-231 cell lines using MTT assay. Compounds 2 and 56 exhibited inhibitory potential against the proliferation of A549, Eca109, HepG2, and MDA-MB-231 cell lines (IC $_{50}$ s ranged from 22.17 to 49.43 μ M), comparing to vincristine (IC $_{50}$ 0.35–1.47 μ M)⁶⁰ (Table 3).

Cytotoxic evaluation of 7 and **80** *versus* HepG2, U2OS, and MCF-7 cell lines in the MTT revealed that only 7 had cytotoxic influence *versus* MCF-7 and U2OS cells (IC $_{50}$ S 16.8 and 11.6 μ M, respectively). Additionally, in the MTT assay *versus* A549, HeLa and HepG2 cell lines of **8**, **17**, and **18**, only **18** had cytotoxic potential *versus* A549 cell lines (IC $_{50}$ 15.7 μ g mL $^{-1}$).

Cytosporaphenone A (43), a new polyhydric benzophenone was isolated from Morinda officinalis-accompanied *Cytospora rhizophorae* A761 by $SiO_2/RP-18/Sephadex$ LH-20 CC and characterized by spectroscopic and Xray analyses. It revealed weak growth inhibition potential against MCF-7 and HepG-2 (IC $_{50}$ 70.0 and 60.0 μ M, respectively) in the SRB method. 52

Chen *et al.* purified shiraone A (53), a new benzophenone derivative from the cultures of *Shiraia* sp. BYJB-1isolated from *Selaginella delicatula* leaves that was characterized by NMR, HRMS, and comparing with literature (Fig. 6). It had no cytotoxic effectiveness *versus* SMMC7721 cell line.⁵⁹ This compound was proposed to be biosynthesized from 3,4,5-trimethoxybenzoic acid (I) and 2-hydroxy-4-methoxy-6-methylbenzoic acid (II), that were formed by shikimic acid and acetate-malonate pathways, respectively⁵⁹ (Scheme 3).

Xu *et al.* reported the separation of five new benzophenone derivatives: tenellones D-H (73-77), sharing a rare aldehyde at C-2 and isoprenyl at C-6, together with the known metabolite **69** from marine sediment-derived *Phomopsis lithocarpus* FS508

CH₂OCH₃

он н

OH

Fig. 6 Structures of benzophenones 46-51.

using SiO₂/Sephadex LH-20/semipreparative HPLC, which were assigned by spectroscopic and Xray analyses. Their cytotoxic activities *versus* SF-268, HepG-2, MCF-7, and A549 cell lines

CI

CI

OCH₃

Scheme 3 Biosynthetic pathway of shiraone A (53).⁵⁹ DAHP: 3-deoxy-*d*-arabino-heptulosonate 7-phosphate; DHQS, 3-dehydroquinate synthase.

revealed the moderate effectiveness of 77 versus HepG-2 and A549 cell lines (IC $_{50}$ s 16.0 and 17.6 μ M, respectively). Whilst other compounds had no cytotoxic capacity even at Conc. 50 μ M (Fig. 7). ⁶⁵

CH2CH=C(CH3)2

It was noted that metabolites with an isoprenyl group in ring A had no activity (*e.g.*, 77 *vs.* 73–76 and 69)⁶⁵ (Fig. 8). Additionally, new benzophenone analogues: 78, 79, 103, and 104 were characterized from the same fungus by Liu *et al.* utilizing NMR, ECD, and Xray analyses. Their potential anticancer activities *versus* SF-268, MCF-7, HepG-2, and A549 cell lines were




Fig. 7 Structures of benzophenones 52-60

| R₃ Q QH | Compd No. | R1 | R2 | R3 | R | | R ₁₀ C | Ì | Н | R ₂ | |
|------------------------------------|-----------|------------------|-------|------------------|-----------|-----|-------------------|--------------|------------|-----------------|------|
| i, I I | | _ | | | | 9 | abla | \checkmark | \searrow | rt ₂ | |
| | 61 | OCH ₃ | ОН | OCH3 | | L | IJ | Į | 7 | | |
| | 62 | ОН | ОН | OCH ₃ | | | 1 | N | _ | R_3 | |
| H ₃ CO R ₁ | 63 | OCH ₃ | O-Glu | OCH ₃ | | d | нсно | R₅ k | 4 | | |
| R ₂ | 64 | OCH ₃ | O-Glu | ОН | | А | - 1 | ~ | | | |
| | | _ | | _ | | | , - | - 1 | | | |
| OH O R ₁ ~ 1 | Compd No. | R1 | R2 | | | _ | | OH | | | |
| СООН | 65 | СНО | CI | 7 | B= \$O | | | | | | |
| | 66 | соон | CI | | | | | | OII | | |
| | 67 | СНО | н | _ | Compd No. | R2 | R3 | | | R9 | R10 |
| l dou | | | 111 | | | 112 | IN. | R4 | R5 | K9 | ILZO |
| R ₂ dcH ₃ OH | | | 1" | _ | 68 | Н | CH ₃ | H H | ОН | ОН | A |
| R ₂ och ₃ | | | - " | ┙ | | | | _ | _ | | _ |
| ¹ 2 \ | | | 10 | _ | 68 | н | CH ₃ | н | ОН | ОН | А |

Fig. 8 Structures of benzophenones 61–73. *, ** Same nomenclature but different structures.

Review RSC Advances

| R ₂ OH CH | \downarrow | | , ' | HO | | OH L L | ,R ₁ | R ₅ | R ₆ OH | R ₁ | ` | A = 1 | 7 | C= | *** |
|----------------------|-------------------|----|--------|-----------|----|--------------|------------------|----------------|-------------------|----------------|----|-------|----|----|------------------|
| ' ' | | O | ۱۱, | | _ | - | _ | | Compd No. | R1 | R2 | R3 | R4 | R5 | R6 |
| B= 20 | / n=3 | لم | / | Compd No. | R1 | R2 | R3 | | 88 | В | н | ОН | н | Α | ОН |
| 7 1 | | | r | 80 | cı | CI | OCH, | | 89 | СНО | н | ОН | н | С | OCH ₃ |
| , | \$ [™] , | | | 81 | Br | н | OCH ₃ | | 90 | СНО | н | ОН | н | D | OCH ₃ |
| E=20 | LÌ | Ĺ | | 82 | н | Br | ОН | | 91 | ОН | ОН | СНО | н | Α | ОН |
| - 4 ~ | v | _ | _ | 83 | Br | Br | OCH ₃ | | 92 | ОН | н | СНО | Α | Н | ОН |
| Compd No. | R1 | R2 | 7 | 84 | н | CI | ОН | | | | | | | | |
| 74 | В | A | | 85 | cı | н | OCH ₃ | | | | | | | | |
| 75 | С | A | 1 | 86 | Br | CI | OCH ₃ | | | | | | | | |
| 76 | D | A | 1 | 87 | cı | Br | OCH ₃ | | | | | | | | |
| 77 | 0-A | н | 1 | | _ | _ | - | | | | | | | | |
| 78 | ОН | A | 1 | | | | | | | | | | | | |
| 79 | E | Α |] | | | | | | | | | | | | |

Fig. 9 Structures of benzophenones 74-92.

evaluated using the SRB method. Compound **103** demonstrated moderate inhibition potential *versus* SF-268 cell line (IC₅₀ 11.36 μ M), comparing to cisplatin (IC₅₀ 3.25 μ M), while, **78**, **79**, and **104** had weak effectiveness (IC₅₀s 29.49–44.48 μ M).⁶⁶ On the other hand, **129** showed cytotoxicity towards CHO, HepG2, MRC5, and HEK293 with IC₅₀ 9.0–25.0 μ M in the MTT assay.⁸⁵

New halogenated benzophenone derivatives: pestalones B-H (81-87), in addition to 80 and 99 were obtained from the EtOAc extract of Pestalotiopsis neglecta that was cultured in fermentation media supplemented with halide salts using SiO2 CC and RP-HPLC and defined by spectroscopic and Xray analyses (Fig. 9). Compounds 82 and 84 displayed the most powerful anti-proliferation potential versus PANC-1 cells (IC50s 7.6 and 7.2 μ M, respectively), comparing to 5-Fu (IC₅₀ 15.0 μ M), while 85, 80, and 86/87 mixture had less potent effectiveness (IC₅₀ 14.0 μ M) than 82 and 84 but better than 81 (IC₅₀ 26.0 μ M) in the MTT assay. It was indicated that a second halogen atom and/or a methoxy in ring B substitution had no effect on the potency of these metabolites. In addition, 82 and 84 significantly repressed the PANC-1 cells' colony formation in the colony formation assay that supported their anti-proliferation ability of PANC-1 cells via boosting the caspase-3 and PARP's cleavage resulting in PANC-1 apoptosis.69 They possible induced their effect through prohibition of ERK/MEK pathway.69

In the cytotoxicity assay, **68, 80, 84,** and **85** with a C-14 aldehyde group exhibited cytotoxic effectiveness ($IC_{50} < 10.0$ µM) *versus* A549, HeLa, HepG2, MCF-7, and Vero in the MTT




Fig. 10 Structures of benzophenones 93-108.

Fig. 11 Structures of benzophenones 109-122.

assay, whereas **51**, **97**, **98**, and **99** with oxygenated CH_2 -14 had no ($IC_{50} > 50.0 \mu M$) or weak cytotoxic potential (IC_{50} : 23.2–35.8 μM) towards the tested cells, revealing the substantial role of C-14 aldehyde in cytotoxic effect of pestalones and related congeners. Whilst chlorination slightly decreased the activity.⁵⁷

The red alga *Grateloupia turuturu*-derived *Penicillium chrysogenum* AD-1540 yielded two new benzophenone derivatives **95** and **96**. Their structures and configuration were characterized relying on spectroscopic, coupling constants, and TDDFT calculations of ECD spectra. These metabolites are structural related to xanthones, while they featured an uncommon fused dihydropyran ring and an opened ring C. Both compounds revealed moderate to weak cytotoxic potential (IC₅₀s 20.4–46.7 μ M) *versus* BT-549, A549, HeLa, MCF-7, HepG2, and THP-1 cell lines in the CCK-8 method compared to epirubicin (IC₅₀s 2.9 to 7.2 μ M).⁷⁴

In 2017, Lei *et al.* also reported the separation of **99** from a culture of *Phakellia fusca*-associated *Pestalotiopsis heterocornis* that was assessed for cytotoxic potential *versus* BGC-823, H460, PC-3, and SMMC-7721 in the MTT assay (Fig. 10). This compound displayed marked activity *versus* BGC-823 and SMMC-7721 (IC $_{50}$ S 6.8 and 7.9 μ M, respectively) compared to adriamycin (IC $_{50}$ S 1.5 and 2.2, respectively), whereas it was




Fig. 12 Structures of benzophenones 123–131.

Fig. 13 Structures of benzophenones 132–139

moderately active *versus* PC-3 and H460 (IC₅₀s 28.1 and 23.6 μ M, respectively).⁷⁶

The cytotoxicity investigation of **114–117** *versus* HepG-2, H460, MCF-7, and SF-268 cell lines in the SRB method revealed the weak potential of **115** and **117** (IC₅₀ ranged from 29.4 to 68.6 μ M) *versus* these cell lines⁸² (Fig. 11 and 12). Compounds **10**, **25**, and **127** were assessed for their cytotoxic potential *versus* HepG2 using the MTT assay. Among them, **127** was the most active (IC₅₀ 5.2 μ M) than the its related monomers **10** and **25** (IC₅₀s 63.5 and 60.2 μ M, respectively) in comparison to 5-Fu (IC₅₀ 19.2 μ M).³⁶

From the unidentified fungus MSX 17022 belonging to Hypocreales, **1**, **123**, and **125** were separated (Fig. 12). In the SRB assay, **123** possessed cytotoxic effectiveness *versus* MCF-7, H460, and SF268 (IC₅₀s 18.1, 13.6, and 21.4 μ M, respectively), however, **125** had noticeable activity *versus* H460 and SF268 (IC₅₀s 20.6 and 21.0 μ M, respectively). In the brine shrimp lethality, **28** exhibited lethality potential (LD₅₀ 25.3 μ M), compared to colchicine (LD₅₀ 1.22 μ M). Also, **10** and **127** reported from *Solanum insanum*-associated *Aspergillus fumigatus* displayed brine shrimp toxicity (IC₅₀ 74.2 μ M) (Fig. 13).³⁷

In 2017, Liao *et al.* reported the purification of novel diastereomeric lipo-peptidyl benzophenones: asperphenins A (146) and B (147) from the MeOH extract of marine-derived *Aspergillus* sp. using RP-18 CC and HPLC, which were characterized based on spectroscopic, CD, and ECD analyses, as well as Mosher's method. These compounds are C-17 epimers, having R and S configuration, respectively and their structures involve trihydroxybenzophenone, 3-hydroxydodecanoic acid, and tripeptide moieties. Both 146 and 147 exhibited significant anti-proliferative activity *versus* RKO, SNU638, SK-HEP-1, and MDA-MB-231 cell lines (IC $_{50}$ S ranged from 0.8 to 9.7 μ M) in the MTT

assay. It is worth that RKO cells were the most sensitive cell lines towards 146 and 147 (IC₅₀s 0.8 and 1.1 µM, respectively), compared to etoposide (IC₅₀ 3.3 µM).88 In 2020, Bae et al. also reported the antitumor potential of 146 and 147 versus SK-HEP-1, RKO, MAD-MB-231, and SNU638 cell lines (IC₅₀s ranged 0.84-6.48 μM for **146** and 1.26–9.43 μM for **147**). Further, studying the antiproliferative mechanism of 146 on RKO cells revealed that 146 suppressed RKO growth via arresting G2/M cell cycle through prohibiting microtubule polymerization with subsequent apoptosis. It also induced reactive oxygen species and repressed the tumor growth in a colon cancer xenograft model without any toxicity. Interestingly, it possessed synergistic influence with irinotecan (topoisomerase I inhibitor), however, it had antagonistic influence with paclitaxel that indirectly supported their opposite molecular mechanisms. It was found that the aryl ketone moiety is accountable for 146's activity.96 Therefore, 146 could be new lead metabolite for finding out chemotherapeutic agents with antimitotic capacity.

In the same aspect, Byun et al. demonstrated that 147 possessed potent cytotoxic potential versus human CRC (colorectal cancer) cell lines: HCT-116, RKO, Ls174T, and SW480 (IC₅₀s ranged from 0.93 to 47.18 μ M) compared to etoposide in the SRB assay. Compound 147 was found to induce cell cycle arrest at G2/M phase and with subsequent apoptotic cell death, also, it suppressed tumor growth in a xenograft model. 95 Its G2/ M phase arrest influence was accompanied with the check-point proteins (Cdc25c and Chk1/2) regulation, whereas its apoptosis potential was linked to survivin down-regulation and cleaved caspases and p53 upregulation. Further, it boosted the repression of HCT-116 cells invasion and migration through GAPDH (glyceraldehyde-3-phosphate dehydrogenase) downregulation. Also, it upregulated E-cadherin and down-regulated Snail and N-cadherin, confirming its antimetastatic effectiveness. Hence, its antimetastatic and antitumor potential was determined to be due to modulating GAPDH-induced EMT processes. This highlighted the potential of 147 as promising candidate for metastatic CRC treatment.95

3.4. Antioxidant activity

Some of the reported BPs possessed potent antioxidant potential than positive controls. Herein, the reported studies on the antioxidant activity were discussed and the results were listed in Table 4.

In the DPPH assay, 37 and 38 exhibited stronger scavenging potential for DPPH and ABTS radicals (IC₅₀ 1.26 and 1.33 µg mL⁻¹, respectively for DPPH and 0.69 and 0.58 µg mL⁻¹, respectively for ABTS) compared to BHT (butylated hydroxytoluene, IC₅₀ 16.27 µg mL⁻¹ for DPPH) and ascorbic acid (IC₅₀ 3.01 µg mL⁻¹ for ABTS).⁴⁸ A novel derivative, rhizophol A (46) was isolated from the endophytic fungus *Cytospora rhizophorae* A761 and characterized by NMR and Xray, as well as quantum energy calculation. This compound featured unrivalled substituted benzophenone framework, having propionyl and epoxy isopentyl moieties. Compound 46 revealed marked DPPH scavenging capacity (EC₅₀ 13.07 µM), which was powerful than ascorbic acid (EC₅₀ 25.53 µM) in the DPPH assay, suggesting its

| | | Biological results | | |
|-----------|-----------------|----------------------------------|--------------------------------|------|
| Compd no. | Assay/cell line | Compound | Positive control | Ref. |
| 8 | DPPH | 18.9 μM* | Ascorbic acid 11.86 μM* | 33 |
| | CCK-8/PC-12 | 37.38** | Vitamin E 57.68** | 33 |
| 10 | CCK-8/PC-12 | 51.66** | Vitamin E 57.68** | 33 |
| 12 | DPPH | $2.3~\mu {\rm g}~{\rm mL}^{-1}*$ | Trolox 5.4 μg mL-1* | 30 |
| 13 | DPPH | 5.4 μg mL ⁻¹ * | Trolox 5.4 µg mL-1* | 30 |
| 37 | ABTS | 0.69 μg mL ⁻¹ **** | Ascorbic acid 3.01 μg mL-1**** | 48 |
| 38 | DPPH | 1.33 μg mL ⁻¹ * | BHT 16.27 μg mL-1* | 48 |
| | ABTS | 0.58 μg mL ⁻¹ * | Ascorbic acid 3.01 μg mL-1* | 48 |
| 46 | DPPH | 13.07 μM*** | Ascorbic acid 25.53 μM*** | 55 |
| 49 | DPPH | 1.7 μg mL ⁻¹ * | Trolox 5.4 µg mL-1* | 30 |
| 52 | DPPH | 28.62 μM* | Ascorbic acid 25.13 μM* | 58 |
| 57 | CCK-8/PC-12 | 54.22** | Vitamin E 57.68** | 33 |
| 58 | CCK-8/PC-12 | 62.40** | Vitamin E 57.68** | 33 |
| 59 | CCK-8/PC-12 | 63.24** | Vitamin E 57.68** | 33 |
| 60 | CCK-8/PC-12 | 49.11** | Vitamin E 57.68** | 33 |
| 120 | DPPH | 9.5 μM*** | Ascorbic acid 21.9 µM*** | 83 |

potential as prominent lead compound for developing novel antioxidant drug.⁵⁵

Table 4 Antioxidant activity of the reported fungal benzophenones^a

Xestospongia testudinaria-associated *Aspergillus europaeus* WZXY-SX-4-1 biosynthesized new derivatives: eurobenzophenones A–C (47–49), alongside 8 and 12–15 that were isolated using RP-18 CC and RP-HPLC, in addition their structures were established by spectroscopic analyses, as well as Snatzke method for configuration assignment. Compounds 47 and 48 possess a C15 ester with 2'*R*-configured glycerol moiety, where 48 is a methyl ester of 47. Benzophenones 12, 13, and 49 revealed powerful DPPH radical scavenging potential (IC₅₀s 2.3, 5.4, and 1.7 μg mL⁻¹ respectively), while other metabolites had moderate efficacy (IC₅₀ s ranged 11.6–25.3 μg mL⁻¹), compared with trolox (IC₅₀ 5.4 μg mL⁻¹).³⁰

The new metabolite, 52 obtained from Aspergillus fumigatus SZW01 had significant free radical scavenging capability. In the ABTS assay, 52 possessed stronger potential than ascorbic acid (IC₅₀ 12.5 μ M), however, it had relatively weak potential (IC₅₀ 28.62 μM) in the DPPH assay compared to ascorbic acid (IC₅₀ 25.13 μM).⁵⁸ Cave soil-derived Aspergillus fumigatus GZWMJZ152 yielded new sulphur-having benzophenones: 57-60, in addition to 8 and 10 that were separated utilizing SiO₂/Sephadex LH-20/ RP-18 CC and preparative TLC. Their structures and absolute configurations were proved by spectroscopic, X-ray, and ECD analyses. Compound 57 represents an uncommon hybrid of diketopiperazine-benzophenone via a thioether linkage. Compound 57 with 6'R-configuration involves cyclo-Gly-Cys diketopiperazine that is S-linked to monomethylsulochrin framework (10). Both 58 and 59 were initially separated as racemic mixtures that were then purified as the enantiomerically pure (+)-58, (-)-58, (+)-59, and (-)-59, respectively. Compound 58 was assigned as R-(+)- and S-(-)-2-methylsulfinyl monomethylsulochrin that have rare methyl sulfinyl group, while 59 featured 2-methoxy-1,4-oxathiane that was linked into the C-2/C-3 bond of sulochrin nucleus. Besides, 60 has a methyl mercaptoacetate moiety connected via a thioether to the C-2 of monomethylsulochrin nucleus. These metabolites were investigated for antioxidant potential by assessing DPPH scavenging potential and ORAC index as well as protective potential versus H₂O₂produced oxidative damage on PC12 cells. The results revealed that 8 scavenged DPPH radicals (IC₅₀ 18.90 μM), compared to vitamin C (IC₅₀ 11.86 μ M), while **10**, **57**, (\pm)-**58**, (+)-**58**, (-)-**58**, (\pm) -59, (+)-59, and (-)-59 exhibited potent antioxidant capacities with ORAC ranging from 0.02 to 6.14 μ M TE μ M⁻¹. Furthermore, compounds 8, 57, (\pm) -58, (\pm) -59, and 60 revealed protection efficacy on H₂O₂-induced oxidative injury on PC12 cells (% viability 51.66, 54.22, 62.4, and 63.24, respectively) in the CCK-8 assay compared to vitamin E (% viability 57.68).33 Recently, cytorhizophin J (120) was obtained from the EtOAc extract of Cytospora heveae NSHSJ-2 isolated from the fresh stem of Sonneratia caseolaris by SiO2, Sephadex LH-20 CC, and HPLC. This compound was similar to 45 with C-13 5-methoxy-5-oxopentanoyl moiety instead of propionyl group at the C-13 in 45. It (EC₅₀ 9.5 μM) showed marked antioxidant potential compared to ascorbic acid (EC₅₀ 21.9 µM) in the DPPH assay.83

3.5. Immune-suppressive activity

Most of the immunological disorders are resulted from immune cells' abnormally low or over activity. In immune-system overactivity, the body damages and attacks its own tissues referring to an acquired immune system reaction. Immune-suppressants are utilized to control autoimmune disorders and improved allograft survival, however, they possess deleterious side effects.⁹⁷

From the EtOAc extract of *Penicillium* sp. ZJ-SY2 isolated from *Sonneratia apetala* leaves, two new benzophenone derivatives; peniphenone (39) and methyl peniphenone (40) were separated using SiO₂/Sephadex LH-20/RP-HPLC. Their immunosuppressive potential *versus* Con A-caused T cell and LPS-induced B cell proliferations of mouse splenic lymphocytes in

Table 5 Other activities of the reported fungal benzophenones

| | | Biological resu | ults (IC ₅₀) | |
|---|--|-------------------------|--|------|
| Compound name | Assay, organism, or cell line | Compound | Positive control | Ref. |
| Anti-inflammatory | | | | |
| 3-de- <i>O</i> -Methylsulochrin (12) | LPS/Spectrophotometric | 71.0% ^a | MG132 88.9% ^a | 30 |
| Dipleosporone A (137) | LPS/Spectrophotometric | 8.8 μM | Dexamethasone 22.2 μM | 63 |
| Dipleosporone B (138) | LPS/Spectrophotometric | 15.6 μM | Dexamethasone 22.2 μM | 63 |
| Dipleosporone C (139) | LPS/Spectrophotometric | 18.1 μΜ | Dexamethasone 22.2 μM | 63 |
| Antimalarial | | | | |
| Orbiocrellone B (132) | GFP/P. falciparum K1 | 5.7 μM | Dihydroartemisinin 0.0025 μM | 53 |
| Orbiocrellone C (133) | GFP/P. falciparum K1 | 5.6 μM | Dihydroartemisinin 0.0025 μM | 53 |
| Orbiocrellone D (134) | GFP/P. falciparum K1 | 14.0 μM | Dihydroartemisinin 0.0025 μM | 53 |
| Ent-secalonic acid I (144) | GFP/P. falciparum K1 | 5.5 μM | Dihydroartemisinin 0.0025 μM | 53 |
| SOAT inhibitory | | | | |
| FD549 (88) | SOAT1, African green monkey (CHO)/ Cell based | 9.9 μΜ | _ | 70 |
| | SOAT2, African green monkey (CHO)/ Cell based | 0.91 μΜ | _ | 70 |
| | SOAT1, Human/Cell based | 5.2 μM | _ | 70 |
| | SOAT2, Human/Cell based | 0.68 μM | _ | 70 |
| Celludinone B (143) | SOAT1, African green monkey (CHO)/ Cell based | 2.8 μ M | _ | 70 |
| | SOAT2, African green monkey (CHO)/ Cell based | 0.15 μΜ | _ | 70 |
| | SOAT1, Human/Cell based | 2.9 μΜ | | 70 |
| | SOAT2, Human/Cell based | 0.069 μΜ | | 70 |
| α-Glucosidase inhibitory | | | | |
| 3-de- <i>O</i> -Methylsulochrin (12) | Colorimetric | 0.199 μΜ | Quercetin 0.015 μM Acarbose 0.685 μM | 38 |
| Immunosuppressive Peniphenone (39) | Moyee calenie lymphogytes/Con A | 8.1 μg mL ⁻¹ | Azathioprine 2.7 $\mu g \; m L^{-1}$ | 49 |
| Pemphenone (39) | Mouse splenic lymphocytes/Con-A Mouse splenic lymphocytes/LPS | 9.3 μg mL ⁻¹ | Azathioprine 2.7 $\mu g \text{ mL}^{-1}$ | 49 |
| Anti-toxoplasmosis | | | | |
| Tenellone A (69) | Eimeria tenella (EtPKG)/radiometrically | 12 . 6 μM | Synthetic refence compound <0.001 μM | 64 |
| Tenellone B (70) | Eimeria tenella (EtPKG)/radiometrically | 8.7 μ M | Synthetic refence compound <0.001 μM | 64 |
| Anti-coccidiosis Tenellone A (69) | Toxoplasma gondii (TgWC)/β-galactosidase, colorimetrically | 1.8 μΜ | Synthetic refence compound 210.0 μ M | 64 |

the MTT method was evaluated. Compound **39** displayed potent immunosuppressive effectiveness (IC $_{50}$ S 9.3 and 8.1 µg mL $^{-1}$, respectively) *versus* LPS- and Con A-induced proliferations of mouse splenic lymphocytes compared to azathioprine (IC $_{50}$ 2.7 µg mL $^{-1}$), while **40** had weak influence (IC $_{50}$ S 23.7 and 17.5 µg mL $^{-1}$, respectively) (Table 5). It was found that C-1 carboxylic acid group boosted the activity, compared to **40** bearing a methyl ester group.⁴⁹

3.6. Anticoccidial and anti-malarial activities

Eimeria spp. causes coccidiosis, which is a significant parasitic disease affects chickens, resulting in serious economic losses through mortality and morbidity. The anticoccidial agents such

as polyether ionophore are successfully utilized in poultry industry. Unfortunately, resistance has been observed to the existing anti-coccidiosis agents, therefore, search for new therapeutic agents for coccidiosis control are needed.⁹⁸

Bioassay-guided fractionation of *Diaporthe* sp. associated with *Aeonium cuneatum* stems resulted in the purification of **69** and **70**, two new highly substituted benzophenones from the methyl ethyl ketone extract using Sephadex LH-20 and HPLC, which were determined by spectroscopic and Xray analyses. They featured trioxygenated isopentane and 1,4-dioxane moieties, respectively. Their *Eimeria tenella* PKG (cGMP-dependent-protein kinase) and *Toxoplasma gondii* whole cell (TgWC) inhibition capability was estimated using radiometric and β -

Review RSC Advances

galactosidase whole cell reporter assays, respectively. Compound **69** prohibited EtPKG (IC $_{50}$ 12.6 μ M) and had notable TgWC inhibitory potential (IC $_{50}$ 1.8 μ M) compared to a synthetic reference (IC $_{50}$ < 0.001 and 210.0 μ M, respectively), while **70** demonstrated potential on EtPKG (IC $_{50}$ 8.7 μ M). Unfortunately, neither **69** nor **70** displayed anticoccidial potential on *Eimeria*-affected chickens (dose 100 ppm).

Investigation of the insect-associated Orbiocrella petchii BCC 51377 EtOAc extract using RP-18/SiO₂/Sephadex LH-20 CC and RP-HPLC resulted in orbiophenone A (44, benzophenone derivative), orbiocrellone A (131, homodimer of 44), orbiocrellones B-E (132-135, chromone-benzophenone heterodimers), and ent-secalonic acid I (144, tetrahydroxanthonebenzophenone dimer) that were elucidated by spectroscopic and chemical analyses, additionally their absolute configuration was established by ECD spectra and ECD-TD-DFT calculation. Compound 131 is a C-11-C-11' symmetric homodimer of 44. Besides, 133 is an isomer of 132, differing in the dimerization position and 144 with 5'S/6'R/10a'S configuration is an enantiomer secalonic acid I formerly reported from *Penicillium* oxalicum.99 Compounds 132, 133, 134, and 144 revealed antimalarial potential versus Plasmodium falciparum K1 (IC₅₀s 5.7, 5.6, 14.0, and 5.5 µM, respectively) compared to dihydroartemisinin (IC50 0.0025 µM) in the microculture radioisotope technique.53

3.7. Anti-inflammation activity

The new derivatives: eurobenzophenones A–C (47–49), along-side 8 and 12–15 (Conc. 10 μ M) exerted inhibition potential *versus* NO production boosted LPS in the BV2 cells (% inhibition 17.4–39.4%), compared to curcumin (% inhibition 60%). Compound 8, 12, and 48 (Conc. 10 μ M) remarkably declined NF-κB expression (inhibitory rates 67.2, 71.0, and 74.9%, respectively), compared to MIG132 (NF-κB inhibitor, 90% inhibitory rate, Conc. 10 μ M).³⁰ The significant inhibitory potential of 48 toward NO was mediated by NF-κB down-regulation.³⁰

Tenellone D (72) a new derivative along with 71 were separated from *Diaporthe* sp. SYSU-HQ3 $\rm CH_2Cl_2$ extract by different chromatographic methods. Compound 72 is related to 71 with a methyl ester moiety instead of the carboxylic acid moiety at C-2 in 71. It was proposed that methyltransferase may be accountable for the C-1 carboxyl group methylation. It is noteworthy that 71 exhibited no inhibition on NO production boosted by LPS in the RAW 264.7 cells (Conc. 100 μ M), however, its C-1 methyl ester 72 possessed (IC50 18.6 μ M) marked inhibitory potential, comparing to indomethacin (IC50 37.5 μ M), suggesting esterification enhanced the activity. Whilst 123 and 125 were inactive in assays for both NF-kB inhibition and mitochondrial transmembrane potential.

New dimeric benzophenones; **137–139** and benzophenone monomers; **61**, **63**, and **64**, along with **55** and **62** were isolated from *Pleosporales* sp. YY-4 associated with *Uncaria rhynchophylla* by SiO₂/RP-18/HPLC and assigned by HREIMS and NMR. Compounds **137–139** are the first C bridged benzophenone dimers. These metabolites were evaluated for their anti-inflammatory activity by examining their inhibition of NO

production induced by LPS in the RAW 264.7 cells using CCK-8 assay. Compounds **64** and **137–139** possessed more noticeable inhibition potential *versus* LPS-caused NO production in the RAW 264.7 cells (IC $_{50}$ ranged from 8.8 to 23.3 μ M) than dexamethasone (IC $_{50}$ 22.2 μ M). The dimeric derivatives **137–139** were more potent than the monomers **61–63** and **55** that displayed moderate anti-inflammation potential (IC $_{50}$ ranged from 35.1 to 43.3 μ M).

3.8. α -Glucosidase, proteasome, and tyrosine phosphatase inhibitory activities

 α -Glucosidase catalyses the glycosidic bonds hydrolysis of nonreducing saccharide polymers to give glucose. 100 α -Glucosidase inhibition controls the postprandial blood level due to slowing the dietary carbohydrates uptake. 101,102 α -Glucosidase inhibitors have been assumed to be therapeutic agents for carbohydrate-related metabolic disorders such as diabetes.

The chemical investigation of the EtOAc extract of *Aspergillus flavipes* PJ03-11 resulted in separation of a new benzophenone, **11**, along with **12** and **21** by repeated $SiO_2/Sephadex$ LH-20 CC/RP-HPLC. Compounds **12** and **21** ($IC_{50}s$ 0.199 and 0.042 μ M, respectively) demonstrated stronger α -glucosidase inhibition potential than acarbose (IC_{50} 0.685 μ M) and quercetin (IC_{50} 0.015 μ M), while **11** ($IC_{50} > 2.0 \ \mu$ M) had modest activity.³⁸ Further, compound **52** was reported to exhibit powerful α -glucosidase inhibition than acarbose.⁵⁸

Fig. 14 Structures of benzophenones 140–147.

RSC Advances Review

KATP channel has a major function in the control of β -cell membrane potential. pancreatic β -cells KATP channel inhibitors help the release of insulin and are used as antidiabetics such as sulfonylureas, however, the usage of KATP channel blockers leads to a high incidence of hypoglycaemic events. ⁵¹ It was reported that voltage-gated K channels modulation could be an alternative in antidiabetic indications. β -cell Kv2.1 (voltage-dependent K⁺) channel contributes to insulin-secreting cell repolarization and regulates pancreatic insulin secretion. ¹⁰³ The β -cell Kv2.1 currents prohibition results in prolongation of the action potentials and sustaining voltage-dependent Ca²⁺ channels opening, therefore enhanced glucose-boosted insulin release without producing risky hypoglycaemia. Therefore, the β -cell Kv2.1 channel is targeted for T2DM treatment. ⁵¹

Two new benzophenones, acredinones A (140) and B (141), along with 42 were separated from the marine sponge-accompanied *Acremonium* sp. EtOAc extract utilizing SiO₂ CC and RP-HPLC (Fig. 14). Their structures were elucidated by spectroscopic data and chemical derivatization. They were assayed for inhibition of the outward K^+ currents in INS-1. Compounds 140 and 141 revealed notable inhibitory potential on voltage-gated K^+ channel in INS-1 cells (IC₅₀s 0.59 and 1.0 μ M, respectively), while 42 had no inhibitory activity. These metabolites represent the first nonpeptidic natural metabolites, possessing marked outward K+ currents prohibition in INS-1 cells.

Compounds 123 and 125 were moderately effective *versus* 20S proteasome (% inhibition 12.0 and 32.0, respectively, Conc. $5 \mu g \, \text{mL}^{-1}$). Also, 27 purified from ascidian-derived *Penicillium albo-biverticillium* TPU1432 culture broth using RP-18 CC and HPLC (ODS) was assessed for its inhibitory potential on PTP-1B (protein tyrosine phosphatase-1B), TCPTP (T cell PTP), and CD45 (CD45 tyrosine phosphatase) in the colorimetric assay. Compound 27 was found to have inhibitory capacity on CD45, PTP1B, and TCPTP (IC $_{50}$ s 21.0, 36.0, and 20.0 μ M, respectively) compared to oleanolic acid (IC $_{50}$ 0.8, 1.0, and 0.9 μ M, respectively).

3.9. Anti-osteoclastogenic activity

Osteoclasts overactivity results in excessive bone resorption that breaks the bone resorbing/forming balance, leading to osteopenic disorders such as Paget's disease, periodontal disease, osteoporosis, and rheumatoid arthritis. 104 The RANK/RANKL signalling pathway activates substantial signalling molecules for osteoclast function and development. 105 Several reports investigated the inhibitory potential of natural metabolites on RANKL-mediated osteoclast differentiation aiming at discovering new drug leads for treating osteoporosis. 106

A new RANKL-induced osteoclast differentiation inhibitor, acredinone C (142), along with related analogs 140 and 141 were separated from *Acremonium* sp. F9A015 culture broth EtOAc extract utilizing RP-HPLC. Compound 142 incorporates xanthone and benzophenone moieties, that was established by NMR and MS analyses. These acredinones effectively prohibited the RANKL-produced formation of TRAP+MNCs without any toxicity up to 10 μ M. Their anti-osteoclastogenic potential was

correlated with the downstream effectors' blockage *via* downregulating of NFATc1 (nuclear factor of activated-T cells, cytoplasmic 1) expression through inhibiting signalling molecules: ERK, p38, IkBa, and AKT. Further, **140** possessed dual potential on osteo-clasto-genesis and osteo-blasto-genesis, where its osteogenic potential was due to osteoblast-specific genes upregulation through BMP family members control and Smad signalling pathway. Additionally, **140** had marked bone-formation potential in the *in vivo* mouse model, thence, **140** could be a potential lead as an anabolic agent and/or antiresorptive agent to prohibit and heal bone disorders.⁸⁷

3.10. Antihyperlipidemic activity

Body stores excessive energy as lipid droplets in adipocytes that act as an energy reservoir. Excessive storage of lipids was found to be a cause of diverse disorders, including cardiovascular disease, T2DM, and atherosclerosis.¹⁰⁷

Chemical examination Cinachyrella sp.-associated Emericella variecolor resulted in separation of a new metabolite; 19-Omethyl-22-methoxypre-shamixanthone (93), together with 94 using SiO₂/RP-18/Sephadex LH-20 and semipreparative HPLC that were elucidated based on extensive spectroscopic, ECD, and Xray analysis as well as Mosher's method. These metabolites were examined for lipid-lowering potential on OA (oleic acid)-elicited lipid accumulation in the HepG2 cells by measuring Oil Red O staining. Compound 94 exerted marked lipid accumulation inhibition potential (Conc. 10 µM) comparable to that of simvastatin accompanied with potent reducing of intracellular TG (triglyceride) and TC (total cholesterol), without toxicity toward HepG2 cells up to 100 μM in the MTT assay. It mediated its lipid accumulation inhibitory potential through down-regulating the expression of the principal lipogenic transcriptional factor; SREBP-1c (sterol regulatory element-binding transcription factor 1) and its down-stream genes, including FAS (fatty acid synthase) and ACC (acetylCoA carboxylase). Thence, it lessened lipid accumulation via SREBP-1 pathway downregulation with no toxicity, suggesting its potential as lead compound for developing anti-hyperlipidemic agent.73

3.11. Sterol O-acyltransferase inhibitory activity

SOAT-2 (sterol *O*-acyltransferase-2) is belonging to the membrane-bind *O*-acyl-transferase family that adjusts the body metabolism of cholesterol. ^{70,108} It is principally expressed in the small intestine and hepatocytes. It has been reported as a substantial target for treating/preventing atherosclerosis and hypercholesterolemia than SOAT1. ⁷⁰

A new indanone analog: celludinone B (143), along with 88 were purified from *Talaromyces cellulolyticus* BF-0307 culture broth by RP-18 CC and HPLC and assigned by NMR spectral data. Their SOAT (sterol *O*-acyltransferase) inhibition potential was assessed on SOAT-1(sterol *O*-acyltransferase-1) and SOAT-2 (sterol *O*-acyltransferase-2) isozymes in the cell-based assay using SOAT-1- and -2-CHO (Chinese hamster ovary) cells. Compounds 88 and 143 displayed noticeable SOAT-1 and SOAT-2 inhibitory capacity (IC $_{50}$ s 9.9 and 0.91 μ M for 88 and 2.8 and

Review RSC Advances

0.15 μ M for 143, respectively). Interestingly, both 88 and 143 were SOAT2 selective inhibitors, suggesting that the benzophenone moiety in 88 and 143 was substantial for SOAT-2-selective inhibition (Table 5). Similar findings were noted on using human SOAT-1- and SOAT-2-expressing CHO cells without toxic effect in these cell lines even at 20 μ M.⁷⁰

3.12. Phytotoxic and insecticidal activities

Phytotoxic constituents act as pathogenicity or virulence factors in pathogen-host interactions and in the infectious mode. ^{109,110} The separation of such metabolites assists in understanding their potential in the induction of disease symptoms and phytopathogenic processes that could help in assigning disease management. ^{109,110} Additionally, these metabolites can be used as potential herbicides.

Rabenzophenone (2), a new hexa-substituted derivative, along with 1 were separated by SiO₂ CC and preparative TLC from the extract of *Fimetariella rabenhorstii* obtained from *brantii brantii* (Iranian oak) infected stems. Compound 2 is related to 1, but it has an extra C-4 chlorine atom. These compounds exhibited phytotoxic potential on tomato and holm oak leaves (Conc. 1 mg mL⁻¹), causing a necrosis (diameter ranged from 0.2 and 0.5 cm) in the leaf puncture bioassay, whereas 2 was the most phytotoxic one.²¹ Additionally, they were separated from the solid culture of *Alternaria sonchi (Sonchus* spp. (sowthistles) leaf pathogen). They had phytotoxic effectiveness on *Elytrigia repens* (couch-grass) and *Sonchus arvensis* (sowthistle) leaves in the punctured leaf disc assay.¹¹⁰

Compounds **8**, **16**, **19**, and **20** were assessed for their insecticidal potential by inhibiting the growth of newly hatched *Helicoverpaarmigera* Hubner larvae. They were found to possess growth inhibition potential (IC₅₀s 200, 200, 200, and 100 μ g mL⁻¹, respectively), compared azadirachtin (IC₅₀ 50 μ g mL⁻¹).³²

3.13. Protein kinase inhibitory activity

Chromatographic investigation of the *n*-BuOH fraction of *Verticillium balanoides* mycelia that was collected from *Pinus*

palustris needle litter near Hoffman, North Carolina utilizing Sephadex LH-20 and HPLC afforded balanol (109) that was assigned by MS, Xray, and NMR data. This compound demonstrated potent PKCs (protein kinase Cs: α , β -I, β -II, γ , δ , ϵ , and η) inhibitory potential (IC $_{50}$ S ranged from 4–9 nM).

4 Conclusions and future prospective

It is apparent that fungi are capable of creating medicinally valuable metabolites that have been established to possess novel action mechanisms that hold great promise as prospected drug candidates. From 1963 to October 2022, 146 benzophenone derivatives were separated from fungal sources, particularly from endophytic fungi. Most of them were reported in the period from 2018 to 2022, the decrease in the number of reported metabolites in 2020 and 2021 may be due to COVID-19 pandemic (Fig. 15).

These metabolites have been reported from 31 fungal genera: Monilinia, Hypocreales, Penicillium, Fimetariella, Alternaria, Daldinia, Emericella, Cercophora, Pestalotiopsis, Aspergillus, Aureobasidium, Rhizoctonia, Guignardia, Astrocystis, Monodictys, Acremonium, Graphiopsis, Talaromyces, Ascomycota, Cytospora, Orbiocrella, Shiraia, Pleosporales, Diaporthe, Phomopsis, Mericella, Verticillium, Delitschia, Hypocreales, Microsphaeropsis, and Phoma. Most of them are reported from Pestalotiopsis (14 compounds), Cytospora (13 compounds), Penicillium (20 compounds), and Aspergillus (35 compounds) (Fig. 16). These fungal species have been derived from different sources, including marine, endophytes, soil, cultured, and other sources. The major number of metabolites were reported from endophytic and marine-derived fungal species (Fig. 17).

These benzophenone derivatives involved simple, prenylated, and dimeric derivatives. It was found that the mixed fermentation of fungi with other microbes such as bacteria boosted the fungal production of these metabolites. Also, modification of the culture resulted in biosynthesis of new metabolites *e.g.*, 81–87 obtained from halide salts




Fig. 15 Number of benzophenones reported from fungal source per year.

RSC Advances Review




Fig. 16 Number of benzophenones reported from various fungal genera.




Fig. 17 Number of benzophenones reported from fungal species derived from different sources.

supplemented fermentation media. Therefore, these techniques could be applied for discovering new lead metabolites.

These metabolites have been assessed for various bioactivities, the major metabolites ones were evaluated for antimicrobial and cytotoxicity. It is noteworthy that limited studies investigated the anti-inflammation, anti-mycobacterial, antialgal, Plant growth inhibitory, anti-nematode, antioxidant,




Fig. 18 Structural features of benzophenone derivatives and structure–activity relationship (SAR) for different bioactivities.

phytotoxic, insecticidal, antihyperlipidemic, antiosteoclastogenic, immune-suppressive, anticoccidial, and antimalarial, as well as α -glucosidase, proteasome, tyrosine phosphatase, protein kinase, and sterol O-acyltransferase inhibitory activities of these metabolites.

The reported structure-activity studies revealed that the substitution pattern of these class of metabolites was greatly influenced various activities as summarized in Fig. 18.

In some of the assessed activities these metabolites revealed potent effectiveness comparable or more than that of positive control such as antimicrobial (*e.g.*, 22, 23, 37, 80, 99, 128, and 129), cytotoxic (*e.g.*, 68, 83, 84, 146, and 147), antioxidant (*e.g.*, 12, 13, 37, 38, 46, and 49), α -glucosidase inhibitors (*e.g.*, 12 and 21), anti-inflammation (*e.g.*, 72 and 137–139), anti-hyperlipidemic (*e.g.*, 94 and 95), and anti-osteoclastogenic (*e.g.*, 140). Further, prenylated benzophenone 69 had the ability to prohibit the cGMP dependent protein kinase activity of *E. tenella* and also revealed antiparasitic potential against TgWC (apicomplexan parasite *Toxoplasma gondii*).

It is noteworthy that limited studies exploring the mechanism of action of these metabolites were reported. For example, **140** had anabolic and/or anti-resorptive potential through osteoblast-specific genes up-regulation through BMP family members control and Smad signalling pathway that could prohibit and heal bone disorders. Compound **94** mediated anti-hyperlipidemic effect *via* SREBP-1 pathway downregulation. Compounds **146** and **147** possessed potent antimetastatic and antitumor through various mechanisms, suggesting their potential as promising new lead metabolite for finding out chemotherapeutic agents.

These metabolites worthy deserve further investigation as potential leads of therapeutic agents. The benzophenone dimerization *via* a *S*-ether functionality was greatly affected the activity, therefore, this could be a beneficial approach of synthetic research to modulate the selectivity and bioactivity of these metabolites. Future studies on the structure-activity relations, molecular mechanisms, and *in vivo* investigations of these metabolites are highly recommended.

Lastly, fungal benzophenones have diverse and often powerful bioactivities, and it is probable that more metabolites belonging to this class will be brought to light in the coming years. The creation of these metabolites through chemical synthesis could be an interesting area for future research by organic chemists.

List of abbreviations

Microglia cells

BV-2

| A549 | Human lung adenocarcinoma epithelial cell line |
|----------------|--|
| ABTS | 2,2′-Azinobis-(3-ethylbenzthiazoline-6-sulphonate) |
| ACC | AcetylCoA carboxylase |
| AKT | Protein kinase B |
| BGC-823 | Human gastric carcinoma cell line |
| BHT | Butylated hydroxytoluene |
| <i>n</i> -BuOH | <i>n</i> -Butanol |
| BT-549 | Hormone-sensitive breast cancer cell line |

MCF-7

MIC

MNCs

MRSA

MRC5

MptpB

NFATc1

RANKL

NMR

NO

OA ORAC

p38

PKC

PANC-1

MS

MDA-MB-231

Review

| CCD 841 | Human normal colon cell line | PC-3 | Human prostatic-testosterone-independent cell |
|------------|---|------------|---|
| CoN | | | line |
| CCD-18Co | Human normal colon cell line | RANKL | Receptor activator of nuclear factor kappa B ligand |
| CCK-8 | Cell counting kit-8 | RANK | Receptor activator of nuclear factor kappa B |
| CD | Circular dichroism | RKO | Human colon cancer cell line |
| CH_2Cl_2 | Dichloromethane | RP-18 | Reversed phase-18 |
| CHO | Chinese hamster ovary cells | SF268 | Human astrocytoma cell line |
| Con A | Concanavalin A | SRB | Sulforhodamine B |
| CRC | Colorectal cancer cell | SiO_2 CC | Silica gel column chromatography |
| FAS | Fatty acid synthase | SK-HEP-1 | Human hepatic adenocarcinoma cell line |
| DPPH | 1,1-Diphenyl-2-picrylhydrazyl | SMMC- | Human hepatocellular carcinoma cell line |
| DU145 | Human prostate carcinoma cell line | 7721 | |
| EC_{50} | Half maximal effective concentration | SNU638 | Human gastric cancer cell line |
| ECD | Electronic circular dichroism | SOAT2 | Sterol <i>O</i> -acyltransferase 2 |
| EMT | Epithelial-to-mesenchymal transition | SOAT1 | Sterol <i>O</i> -acyltransferase 1 |
| ERK | Extracellular signal-regulated kinase | SREBP-1c | Sterol regulatory element-binding protein-1c |
| EtOAc | Ethyl acetate | SW480 | Human colorectal cancer cell line |
| ESI-MS | Electrospray ionization mass spectrometry | TC | Triglyceride |
| GAPDH | Glyceraldehyde-3-phosphate dehydrogenase | TG | Total cholesterol |
| GFP | Green fluorescent protein | TDDFT | Time-dependent density functional theory |
| GI_{50} | The concentration for 50% of maximal inhibition | THP-1 | Human leukemia monocytic cell line |
| | of cell | TLC | Thin layer chromatography |
| H460 | Human lung carcinoma cell line | U2OS | Human osteosarcoma cell line |
| H_2O_2 | Hydrogen peroxide | Vero cell | Normal african green monkey kidney fibroblasts |
| HCT-116 | Human colon cancer cell line | VLC | Normal-phase vacuum liquid chromatography |
| HEK293 | Human embryonic kidney cell | | |
| TT.T. | TT | | |

Author contributions

Conceptualization, S. R. M. I. and G. A. M.; methodology, S. R. M. I., G. A. M., S. G. A. M., and A. Y. A.; software, S. G. A. M., and A. Y. A.; writing—original draft preparation, S. R. M. I. and G. A. M.; writing—review and editing, S. G. A. M and A. Y. A. All authors have read and agreed to the published version of the manuscript.

Conflicts of interest

There are no conflicts to declare.

References

- 1 S. R. M. Ibrahim, H. Choudhry, A. H. Asseri, M. A. Elfaky, S. G. Mohamed and G. A. Mohamed, *J. Fungi*, 2022, **8**, 504.
- 2 S. R. M. Ibrahim, G. A. Mohamed, R. A. Al Haidari, A. A. El-Kholy, M. F. Zayed and M. T. Khayat, *Fitoterapia*, 2018, **129**, 317–365.
- 3 S. R. M. Ibrahim, S. A. Fadil, H. A. Fadil, B. A. Eshmawi, S. G. A. Mohamed and G. A. Mohamed, *Toxins*, 2022, 14, 154.
- 4 A. S. Abdel-Razek, M. E. El-Naggar, A. Allam, O. M. Morsy and S. I. Othman, *Processes*, 2020, **8**, 470.
- 5 A. M. Omar, G. A. Mohamed and S. R. M. Ibrahim, *J. Fungi*, 2022, **8**, 127.
- 6 A. Merchak and A. Gaultier, *Brain Behav. Immun. Health*, 2020, **9**, 100169.
- 7 T. A. K. Prescott, R. Hill, E. Mas-Claret, E. Gaya and E. Burns, *Biomolecules*, 2023, **13**, 986.

Human cervical epitheloid carcinoma cell line HeLa HepG2 Human hepatocellular liver carcinoma cell line **HPLC** High-performance liquid chromatography IC_{50} Half-maximal inhibitory concentration IC_{90} The concentration that will inhibit 90% of the virions ΙκΒα Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha Kv2.1 Voltage-dependent K⁺ Half maximal lethal concentration LD_{50} Lethal concentration that kills 90% LD_{90} IR Infrared LPS Lipopolysaccharide Human colorectal cancer cell line Ls174T

Human breast adenocarcinoma cell line

Methicillin-resistant Staphylococcus aureus

Mycobacterium tuberculosis protein tyrosine

Nuclear factor of activated T cells, cytoplasmic 1

Receptor activator of nuclear factor-кВ ligand

Human pancreas ductal carcinoma cell line

Minimum inhibitory concentrations

Human breast cancer cell line

Multinucleated osteoclast cells

Human lung fibroblasts

Nuclear magnetic resonance

Mass spectrometry

Multitasking kinase

Protein kinase

phosphatase B

Nitric oxide

Oleic acid

Oxygen radical absorbance capacity

RSC Advances

- 8 K. Bhattarai, M. E. Kabir, R. Bastola and B. Baral, Adv. Genet., 2021, 107, 193-284.
- 9 S. Sanchez and A. L. Demain, Food bioact., 2017, 59-87, DOI: 10.1007/978-3-319-51639-43.
- 10 S. Wu, C. Long and E. J. Kennelly, Nat. Prod. Rep., 2014, 31, 1158-1174.
- 11 K. Surana, B. Chaudhary, M. Diwaker and S. Sharma, Medchemcomm, 2018, 9, 1803-1817.
- 12 O. Cuesta-Rubio, A. L. Piccinelli and L. Rastrelli, Stud. Nat. Prod. Chem., 2005, 32, 671-720.
- 13 F. Mao, Y. He and K. Y. Gin, Environ. Sci. Water Res. Technol., 2019, 5, 209-223.
- 14 H. Cui, Y. Liu, J. Li, X. Huang, T. Yan, W. Cao, H. Liu, Y. Long and Z. She, J. Org. Chem., 2018, 83, 11804-11813.
- 15 K. Surana, B. Chaudhary, M. Diwaker and S. Sharma, MedChemComm, 2018, 9, 1803-1817.
- 16 V. Mustieles, R. K. Balogh, M. Axelstad, P. Montazeri, S. Márquez, M. Vrijheid, M. K. Draskau, C. Taxvig, F. M. Peinado and T. Berman, Environ. Int., 2023, 107739.
- 17 U. M. Acuna, N. Jancovski and E. J. Kennelly, Curr. Top. Med. Chem., 2009, 9, 1560-1580.
- 18 H. Kachi and T. Sassa, Agric. Biol. Chem., 1986, 50, 1669-1671.
- 19 S. Ayers, T. N. Graf, A. F. Adcock, D. J. Kroll, Q. Shen, S. M. Swanson, S. Matthew, C. de Blanco, J. Esperanza, M. C. Wani and B. A. Darveaux, J. Antibiot., 2012, 65, 3-8.
- 20 K. Trisuwan, V. Rukachaisirikul, K. Borwornwiriyapan, S. Phongpaichit and J. Sakayaroj, Tetrahedron Lett., 2014, 55, 1336-1338.
- 21 S. Bashiri, J. Abdollahzadeh, R. Di Lecce, D. Alioto, M. Górecki, G. Pescitelli, M. Masi and A. Evidente, J. Nat. Prod., 2020, 83, 447-452.
- 22 A. Dalinova, L. Chisty, D. Kochura, V. Garnyuk, M. Petrova, D. Prokofieva, A. Yurchenko, V. Dubovik, A. Ivanov and S. Smirnov, Biomolecules, 2020, 10, 81.
- 23 T. Hashimoto, S. Tahara, S. Takaoka, M. Tori and Y. Asakawa, Chem. Pharm. Bull., 1994, 42, 1528-1530.
- 24 N. Kawahara, S. Sekita, M. Satake, S. Udagawa and K. Kawai, Chem. Pharm. Bull., 1994, 42, 1720-1723.
- 25 A. C. Whyte, J. B. Gloer, J. A. Scott and D. Malloch, J. Nat. Prod., 1996, 59, 765-769.
- 26 R. Song, Y. Liu, R. Liu, X. Wang, T. Li, L. Kong and M. Yang, Phytochem. Lett., 2017, 22, 189-193.
- 27 J. Hargreaves, Ghisalberti, J. Park, L. K. Sivasithamparam, B. W. Skelton and A. H. White, J. Nat. Prod., 2002, 65, 7-10.
- 28 A. Shimada, C. Shiokawa, M. Kusano, S. Fujioka and Y. Kimura, Biosci. Biotechnol. Biochem., 2003, 67, 442-444.
- 29 V. Rukachaisirikul, S. Satpradit, S. Klaiklay, S. Phongpaichit, K. Borwornwiriyapan and J. Sakayaroj, Tetrahedron, 2014, 70, 5148-5152.
- 30 X. Du, D. Liu, J. Huang, C. Zhang, P. Proksch and W. Lin, Fitoterapia, 2018, 130, 190-197.
- 31 C. Zheng, H. Liao, R. Mei, G. Huang, L. Yang, X. Zhou, T. Shao, G. Chen and C. Wang, Nat. Prod. Res., 2019, 33, 1127-1134.

- 32 M. Bai, C. Gao, K. Liu, L. Zhao, Z. Tang and Y. Liu, J. Antibiot., 2021, 74, 821-824.
- 33 Y. Xu, W. Liu, D. Wu, W. He, M. Zuo, D. Wang, P. Fu, L. Wang and W. Zhu, J. Nat. Prod., 2022, 85, 433-440.
- 34 C. Yu, S. Lin, X. Ma, J. Zhang, C. Wu, B. Ma, H. Wang and Y. Pei, Nat. Prod. Res., 2021, 1-6.
- 35 Y. M. Ma, Y. Li, J. Y. Liu, Y. C. Song and R. X. Tan, Fitoterapia, 2004, 75, 451-456.
- 36 F. Wang, Y. Ye, H. Ding, Y. Chen, R. Tan and Y. Song, Chem. Biodivers., 2010, 7, 216-220.
- 37 M. V. K. Munasinghe, N. S. Kumar, N. Adikaram, L. Jayasinghe, H. Araya and Y. Fujimoto, Asian J. Tradit. Med., 2021, 16, 76-82.
- 38 L. Zhang, B. Feng, Y. Zhao, Y. Sun, B. Liu, F. Liu, G. Chen, J. Bai, H. Hua and H. Wang, Bioorg. Med. Chem. Lett., 2016, 26, 346-350.
- 39 Y. Ji, W. Chen, T. Shan, B. Sun, P. Yan and W. Jiang, Chem. Biodivers., 2020, 17, e1900640.
- 40 T. Lin, C. Lu and Y. Shen, Nat. Prod. Res., 2009, 23, 77-85.
- 41 J. Kornsakulkarn, S. Saepua, S. Komwijit, P. Rachtawee and C. Thongpanchang, *Tetrahedron*, 2014, 70, 2129–2133.
- 42 A. Krick, S. Kehraus, C. Gerhäuser, K. Klimo, M. Nieger, A. Maier, H. Fiebig, I. Atodiresei, G. Raabe and J. Fleischhauer, J. Nat. Prod., 2007, 70, 353-360.
- 43 H. Luo, X. Li, C. Li and B. Wang, Phytochem. Lett., 2014, 9, 22-25.
- 44 D. A. Sumilat, H. Yamazaki, K. Endo, H. Rotinsulu, D. S. Wewengkang, K. Ukai and M. Namikoshi, J. Nat. Med., 2017, 71, 776-779.
- 45 H. He, R. Bigelis, E. H. Solum, M. Greenstein and G. T. Carter, J. Antibiot., 2003, 56, 923–930.
- 46 D. Pockrandt, L. Ludwig, A. Fan, G. M. König and S. Li, Chembiochem, 2012, 13, 2764-2771.
- 47 T. Asai, S. Otsuki, H. Sakurai, K. Yamashita, T. Ozeki and Y. Oshima, Org. Lett., 2013, 15, 2058-2061.
- 48 H. Li, X. Li, H. Liu, L. Meng and B. Wang, Mar. Drugs, 2016, 14, 223.
- 49 H. Liu, S. Chen, W. Liu, Y. Liu, X. Huang and Z. She, Mar. Drugs, 2016, 14, 217.
- 50 C. Tan, Z. Liu, S. Chen, X. Huang, H. Cui, Y. Long, Y. Lu and Z. She, Sci. Rep., 2016, 6, 1-9.
- 51 H. Kim, I. Yang, S. Ryu, D. H. Won, A. G. Giri, W. Wang, H. Choi, J. Chin, D. Hahn and E. Kim, J. Nat. Prod., 2015, 78, 363-367.
- 52 H. Liu, H. Tan, Y. Liu, Y. Chen, S. Li, Z. Sun, H. Li, S. Qiu and W. Zhang, Fitoterapia, 2017, 117, 1-5.
- 53 M. Isaka, S. Palasarn, W. Choowong, K. Kawashima, S. Mori, S. Mongkolsamrit and D. Thanakitpipattana, Tetrahedron, 2019, 75, 130646.
- 54 H. Liu, H. Tan, W. Wang, W. Zhang, Y. Chen, S. Li, Z. Liu, H. Li and W. Zhang, Org. Chem. Front., 2019, 6, 591-596.
- 55 Z. Liu, H. Tan, K. Chen, Y. Chen, W. Zhang, S. Chen, H. Liu and W. Zhang, Org. Biomol. Chem., 2019, 17, 10009-10012.
- 56 I. C. Form, M. Bonus, H. Gohlke, W. Lin, G. Daletos and P. Proksch, Bioorg. Med. Chem., 2019, 27, 115005.
- 57 Z. Jiang, P. Wu, H. Li, J. Xue and X. Wei, J. Antibiot., 2022, 75, 207-212.

Review

58 B. Liu, N. Chen, Y. Chen, J. Shen, Y. Xu and Y. Ji, *Nat. Prod. Res.*, 2021, 35, 5710–5719.

- 59 D. Chen, S. Zhang, M. Kuang, W. Peng, J. Tan, W. Wang, F. Kang, Z. Zou and K. Xu, *Rec. Nat. Prod.*, 2022, **16**, 471–476.
- 60 Q. Ming, Y. Li, X. Jiang, X. Huang, Y. He, L. Qin, Y. Liu, Y. Tang and N. Gao, *Fitoterapia*, 2022, 157, 105127.
- 61 Y. Sato, T. Oda and H. Saitô, *J. Chem. Soc., Chem. Commun.*, 1978, 135–136.
- 62 A. Rhodes, G. A. Somerfield and M. P. McGonagle, *Biochem. J.*, 1963, **88**, 349.
- 63 H. Zeng, Y. Yu, X. Zeng, M. Li, X. Li, S. Xu, Z. Tu and T. Yuan, *J. Nat. Prod.*, 2022, **85**, 162–168.
- 64 C. Zhang, J. G. Ondeyka, K. B. Herath, Z. Guan, J. Collado, G. Platas, F. Pelaez, P. S. Leavitt, A. Gurnett and B. Nare, J. Nat. Prod., 2005, 68, 611–613.
- 65 J. Xu, H. Liu, Y. Chen, H. Tan, H. Guo, L. Xu, S. Li, Z. Huang, H. Li and X. Gao, *Mar. Drugs*, 2018, 16, 329.
- 66 H. Liu, Z. Liu, Y. Chen, T. Hai-Bo, S. Li, D. Li, H. Liu and Z. Wei-Min, *Chin. J. Nat. Med.*, 2021, 19, 874–880.
- 67 M. Cueto, P. R. Jensen, C. Kauffman, W. Fenical, E. Lobkovsky and J. Clardy, *J. Nat. Prod.*, 2001, **64**, 1444– 1446.
- 68 C. Wang, Y. Wang, X. Zhang, M. Wei, C. Wang and C. Shao, *Chem. Nat. Compd.*, 2017, **53**, 1174–1176.
- 69 W. Wang, C. Park, E. Oh, Y. Sung, J. Lee, K. Park and H. Kang, *J. Nat. Prod.*, 2019, **82**, 3357–3365.
- 70 T. Ohshiro, R. Seki, T. Fukuda, R. Uchida and H. Tomoda, *J. Antibiot.*, 2018, 71, 1000–1007.
- 71 G. Xia, L. Wang, H. Xia, Y. Wu, Y. Wang, P. Lin and S. Lin, *J. Asian Nat. Prod. Res.*, 2020, **22**, 233–240.
- 72 A. Kralj, S. Kehraus, A. Krick, E. Eguereva, G. Kelter, M. Maurer, A. Wortmann, H. Fiebig and G. M. König, *J. Nat. Prod.*, 2006, 69, 995–1000.
- 73 Q. Wu, C. Wu, H. Long, R. Chen, D. Liu, P. Proksch, P. Guo and W. Lin, J. Nat. Prod., 2015, 78, 2461–2470.
- 74 D. Zhao, X. Yuan, Y. Du, Z. Zhang and P. Zhang, *Molecules*, 2018, 23, 3378.
- 75 E. Li, L. Jiang, L. Guo, H. Zhang and Y. Che, *Bioorg. Med. Chem.*, 2008, **16**, 7894–7899.
- 76 H. Lei, X. Lin, L. Han, J. Ma, Q. Ma, J. Zhong, Y. Liu, T. Sun, J. Wang and X. Huang, *Mar. Drugs*, 2017, 15, 69.
- 77 H. Liu, Y. Chen, H. Li, S. Li, H. Tan, Z. Liu, D. Li, H. Liu and W. Zhang, *Fitoterapia*, 2019, 137, 104260.
- 78 J. A. Ballantine, D. J. Francis, C. H. Hassall and J. Wright, *J. Chem. Soc. C*, 1970, 1175–1182.
- 79 J. A. Ballantine, V. Ferrito, C. H. Hassall and M. L. Jenkins, *J. Chem. Soc.*, *Perkin Trans.* 1, 1973, 1825–1830.
- 80 P. Kulanthaivel, Y. F. Hallock, C. Boros, S. M. Hamilton, W. P. Janzen, L. M. Ballas, C. R. Loomis, J. B. Jiang and B. Katz, J. Am. Chem. Soc., 1993, 115, 6452–6453.
- 81 H. Liu, H. Tan, K. Chen, L. Zhao, Y. Chen, S. Li, H. Li and W. Zhang, *Org. Biomol. Chem.*, 2019, **17**, 2346–2350.
- 82 H. Liu, H. Tan, Y. Chen, X. Guo, W. Wang, H. Guo, Z. Liu and W. Zhang, *Org. Lett.*, 2019, **21**, 1063–1067.
- 83 G. Zou, T. Li, W. Yang, B. Sun, Y. Chen, B. Wang, Y. Ou, H. Yu and Z. She, *Mar. Drugs*, 2023, **21**, 181.

- 84 D. R. Jayanetti, Y. Li, G. A. Bartholomeusz, G. F. Bills and J. B. Gloer, J. Nat. Prod., 2017, 80, 707–712.
- 85 K. Yoganathan, S. Cao, S. C. Crasta, S. Aitipamula, S. R. Whitton, S. Ng, A. D. Buss and M. S. Butler, *Tetrahedron*, 2008, **64**, 10181–10187.
- 86 S. H. Shim, J. Baltrusaitis, J. B. Gloer and D. T. Wicklow, J. Nat. Prod., 2011, 74, 395–401.
- 87 J. Yeon, H. Kim, K. Kim, J. Lee, D. H. Won, S. Nam, S. H. Kim, H. Kang and Y. Son, *J. Nat. Prod.*, 2016, 79, 1730–1736.
- 88 L. Liao, S. Y. Bae, T. H. Won, M. You, S. Kim, D. Oh, S. K. Lee, K. Oh and J. Shin, *Org. Lett.*, 2017, **19**, 2066–2069.
- 89 M. Exner, S. Bhattacharya, B. Christiansen, J. Gebel, P. Goroncy-Bermes, P. Hartemann, P. Heeg, C. Ilschner, A. Kramer, E. Larson, W. Merkens, M. Mielke, P. Oltmanns, B. Ross, M. Rotter, R. M. Schmithausen, H. Sonntag and M. Trautmann, GMS Hyg. Infect. Control, 2017, 12, Doc05.
- 90 H. Cui, Y. Lin, M. Luo, Y. Lu, X. Huang and Z. She, *Org. Lett.*, 2017, **19**, 5621–5624.
- 91 A. Banyal, V. Thakur, R. Thakur and P. Kumar, *Curr. Microbiol.*, 2021, **78**, 1699–1717.
- 92 R. L. Siegel, K. D. Miller, H. E. Fuchs and A. Jemal, *Cancer J. Clin.*, 2022, **72**, 7–33.
- 93 D. T. Debela, S. G. Muzazu, K. D. Heraro, M. T. Ndalama, B. W. Mesele, D. C. Haile, S. K. Kitui and T. Manyazewal, *SAGE Open Med.*, 2021, **9**, 20503121211034366.
- 94 D. A. Mahvi, R. Liu, M. W. Grinstaff, Y. L. Colson and C. P. Raut, *Cancer J. Clin.*, 2018, 68, 488–505.
- 95 W. S. Byun, E. S. Bae, S. C. Park, W. K. Kim, J. Shin and S. K. Lee, *J. Nat. Prod.*, 2021, **84**, 683–693.
- 96 S. Y. Bae, L. Liao, S. H. Park, W. K. Kim, J. Shin and S. K. Lee, Mar. Drugs, 2020, 18, 110.
- Bamoulid, O. Staeck, F. Halleck, D. Khadzhynov,
 Brakemeier, M. Dürr and K. Budde, *Transpl. Int.*, 2015,
 8, 891–900.
- 98 W. Gilbert, C. Bellet, D. P. Blake, F. M. Tomley and J. Rushton, *Front. Vet. Sci.*, 2020, 7(7), 558182.
- 99 L. Chen, Y. Bi, Y. Li, X. Li, Q. Liu, M. Ying, Q. Zheng, L. Du and Q. Zhang, *Heterocycles*, 2017, **94**, 1766–1774.
- 100 N. A. Alhakamy, G. A. Mohamed, U. A. Fahmy, B. G. Eid, O. A. A. Ahmed, M. W. Al-Rabia, A. I. M. Khedr, M. Z. Nasrullah and S. R. M. Ibrahim, *Life*, 2022, **12**, 384.
- 101 S. R. M. Ibrahim, G. A. Mohamed, M. T. A. Khayat, S. Ahmed and H. Abo-Haded, *Starch Staerke*, 2019, 71, 1800354.
- 102 S. R. M. Ibrahim, G. A. Mohamed, M. T. A. Khayat, S. Ahmed and H. Abo-Haded, J. Food Biochem., 2019, 43, e12844.
- 103 X. Wang, G. Li, J. Guo, Z. Zhang, S. Zhang, Y. Zhu, J. Cheng, L. Yu, Y. Ji and J. Tao, Front. Neurosci., 2019, 13, 1393.
- 104 H. Bi, X. Chen, S. Gao, X. Yu, J. Xiao, B. Zhang, X. Liu and M. Dai, *Front. Med.*, 2017, 4, 234.
- 105 B. F. Boyce and L. Xing, Arthritis Res. Ther., 2007, 9, S1.
- 106 D. Huang, C. Zhao, R. Li, B. Chen, Y. Zhang, Z. Sun, J. Wei, H. Zhou, Q. Gu and J. Xu, *Nat. Commun.*, 2022, **13**, 1–18.

107 G. A. Mohamed, S. R. Ibrahim, E. S. Elkhayat and R. S. El Dine, *Bull. Fac. Pharm. Cairo Univ.*, 2014, 52, 269–284.

RSC Advances

- 108 S. M. Marshall, A. D. Gromovsky, K. L. Kelley, M. A. Davis, M. D. Wilson, R. G. Lee, R. M. Crooke, M. J. Graham, L. L. Rudel, J. M. Brown and R. E. Temel, *PLoS One*, 2014, 9, e98953.
- 109 D. Xu, M. Xue, Z. Shen, X. Jia, X. Hou, D. Lai and L. Zhou, *Toxins*, 2021, **13**, 261.
- 110 A. Dalinova, L. Chisty, D. Kochura, V. Garnyuk, M. Petrova, D. Prokofieva, A. Yurchenko, V. Dubovik, A. Ivanov, S. Smirnov, A. Zolotarev and A. Berestetskiy, *Biomolecules*, 2020, 10, 81.